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APPLICATION OF ADVANCED ANALYTICAL TECHNOLOGIES 
TO DRUG DEVELOPMENT STUDIES AND CANCER DETECTION 
 
RAMAKRISHNA REDDY VOGGU  
 
ABSTRACT  
In the past decade, bioanalytical method development has become an integral part of the 
clinical diagnosis, biomarker discovery, and drug discovery and development. The new 
and emerged bioanalytical techniques allow the quantitative and qualitative analysis of bio 
molecules with remarkably high sensitivity and specificity. Specifically, these 
bioanalytical methods based on LC-MS and methylation-specific PCR are well suited for 
detecting low-abundance metabolites in various biological fluids and DNA in plasma and 
tissues for biomarker investigation. They offer great clinical promise for early disease 
diagnosis and therapeutic intervention. This dissertation broadly organized into two parts, 
part one talks about the application of LC-MS/MS for drug studies and part two converses 
about cancer diagnostics using PCR.    
Part I, The LC-MS/MS quantitative method is essential for the study of pharmacokinetic 
and toxicological properties in drug screening. Dependent on the type of molecule 
analyzed, different methods were established to achieve accurate and reliable detection. 
LC-MS/MS methods were developed and validated for quantitative analysis of an anti-
cancer agent CSUOH0901, and an anti-parasitic agent BMCL26. 
vi 
 
Part II, a Panel of methylated DNA biomarkers for early detection of hepatocellular 
carcinoma (HCC) was developed by using methylation-specific PCR method. We also 
developed combination biomarkers for HCC screening. This marker combination enabled 
sensitive and specific detection of DNA hypermethylation on several tumor-associated 
genes. The studies with FFPE tissue samples successfully differentiated between HCC and 
normal tissue samples.   
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CHAPTER I 
 
 
INTRODUCTION OF APPLICATION OF ADVANCED ANALYTICAL 
TECHNOLOGIES TO SMALL MOLECULES BY CHROMATOGRAPHY AND 
MASS SPECTROMETRY 
 
 
1.1. General introduction of bioanalytical methods and their applications   
Bioanalysis is a term generally used to describe the qualitative and quantitative 
measurements of a compound or their metabolites in biological materials. A bioanalytical 
method mainly contains two components i) Sample preparation ii) detection of the 
compound. Bioanalytical science plays a key role in understanding diseases, clinical 
diagnosis, and drug discovery and development. The technologies in biomedical science 
have made significant progress over recent years. This facilitates bioanalytical method 
development to become an integral component of biomarker discovery, drug 
3 
 
metabolism/pharmacokinetic (DMPK), and toxicological monitoring. Advanced 
technologies and enhancements of conventional platforms emerged from bioanalysis fulfill 
the requirements of clinical and pharmaceutical fields, including the improvement in mass 
spectrometry detection, fast chromatographic separation, high-throughput samples 
pretreatment, and melting curve analysis with high resolution for genomic assays.   
Early diagnosis of diseases has great significance in improving surgical rates and 
minimizing current invasive diagnostic procedures. This leads to another major clinical 
need in the accurate detection of molecular biomarkers for chronic illnesses and cancers. 
The biomarkers study monitors different biological entities including nucleic acids, 
proteins, and metabolites to reflect the pathophysiology and progression of diseases. Ideal 
biomarkers need to be well understood for their functions in the pathogenic process and 
their values for clinical diagnostics, prognostic, and predictive outcomes. However, these 
molecular biomarkers often present in low abundance in the biological samples, bringing 
great challenges in reliable detection and validation. Inspite of these challenges, there are 
a large number of biomarkers developed currently that must be validated in clinical studies 
for their diagnostic and prognostic applications [1]. 
Besides the broad bioanalytical applications in biomarkers discovery, the impressive 
growth of quantitative bioanalysis has been also well documented in pharmaceutical drug 
discovery and development. In the past decade, more than 500 novel drugs were approved 
by U.S. Food and Drug Administration (FDA) to prevent and treat human diseases [2]. 
Each year, more than 3000 on-going clinical trials are carried out in the drug development 
phase [3]. Despite the enormous amount of lead compounds screened in the drug discovery 
phase, the drug development process is costly and risky with very low rate of clinical 
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success. This drives the rational lead optimization in the earliest stage of drug discovery to 
improve the likelihood of drug approval and prevent drug withdrawal on the market. 
Quantitative bioanalysis serves as a major tool for understanding pharmacological 
properties including absorption, distribution, metabolism, and elimination (ADME), as 
well as toxicity to guide the drug screening for lead candidates. 
 
1.1.1. Bioanalysis applications in drug discovery and development 
Drug PK and toxicity properties are key parameters in the screening and optimization of 
lead compounds in the drug discovery phase. An ideal drug candidate should demonstrate 
the ability be absorbed in the blood stream, reach desirable concentration for effective 
activity, and be eliminated without producing toxic metabolites. 
High-throughput PK screening usually starts from in-vitro assay to study the drug-drug 
interaction and metabolism using liver microsomes and hepatocytes as experimental 
systems. However, the in-vitro results cannot truly represent the real physiological 
environment and may lead to a mistaken conclusion about drug metabolism. Therefore, it 
is essential to assess the PK parameters in vivo to improve the candidate selection through 
animal models. 
In order to accurately define the drug behaviors in vitro and in vivo, bioanalytical support 
has been a prerequisite in the pharmaceutical industry. A large amount of compounds 
involved in the lead optimization requires the quantitative method to be accurate, sensitive, 
and high-throughput to facilitate drug discovery. These requirements can be fulfilled by 
accurate sampling procedures, advanced chromatographic and mass spectrometric 
techniques, as well as automated sample preparation methods. 
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1.2. Modern bioanalytical technologies  
Modern bioanalytical technologies have been significantly broadened in the last decade, 
demonstrating its ability inaccurate qualitative and quantitative determination of protein, 
nucleic acids, small molecular metabolites, and drug in biological materials. The major 
methodologies used for proteomics investigation are based on mass spectrometry (MS). 
The dramatic progress of MS instrumentation refines mass accuracy, resolution, and 
dynamic ranges, ensuring the successful detection of low abundance proteins in biofluids 
and structural confirmation with their characteristic precursor and fragment ions. In 
addition, the robust and reliable liquid chromatography (LC) system in low flow rate has 
greatly improved the sensitivity for the MS detection and confidence for structure 
illustration. 
Besides its application in protein analysis, the hyphenation of LC and MS (LC-MS) is 
established as the state-of-the-art methodology for the quantitation of small molecular 
compounds due to its specificity and sensitivity. It is now widely accepted as the preferred 
method for the quantitative measurement of small molecule drugs and endogenous 
metabolites in various biological matrices including plasma, serum, blood, urine, intestinal 
fluid, and tissue. 
With respect to epigenetic biomarker discovery, the majority of DNA methylation assays 
are based on bisulfite reaction, methylation-specific PCR (MSP), and melting curve 
analysis. Sodium bisulfite converts cytosine to uracil at unmethylated CpG site, leaving 
methylated one unchanged. The MSP methods with designed primers selectively amplify 
methylated DNA bringing high analytical specificity and sensitivity. 
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1.2.1. Principals of LC-MS 
 
1.2.1.1. LC separation 
LC is the basic separation platform for bioanalysis. With this technique, the target analyte 
can be separated with interfering protein, salts, and phospholipids content in complicated 
biological materials. The separation mechanisms of liquid chromatography are based on 
the distribution of analyte between the liquid mobile phase and a stationary phase. 
Depending on the different type of stationary phases, different distribution mechanisms are 
applied. 
Adsorption mechanism is applied for both normal-phase (NP) chromatography and 
reverse-phase (RP) chromatography. In NP chromatography, the stationary phase is a polar 
silica gel and the mobile phase is a non-polar solvent such as hexane, pentane, and 
chloroform. NP chromatography is preferable for the non-polar analyte and the retention 
decreases as the non-polarity of analyte increases. Opposite to NP chromatography, the 
stationary phase of RP chromatography uses non-polar silica-based packing materials after 
the surface modification with C8, C18, or phenyl. Accordingly, the retention decreases 
with increasing polarity of the compound and a number of polar solvents. RP 
chromatography is suitable ideally for polar and ionic compounds, which makes it the most 
widely used LC application. The interaction of the analyte with stationary phase and mobile 
phase solvent greatly depends on the hydrophobicity of the analyte. 
Ion-exchange chromatography is based on the ion exchange equilibrium between the ionic 
or polar compounds with the stationary phase. With opposite change with the ionic 
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functional group of the stationary phase, the ionic compounds can be retained. The elution 
speed is related to the ionic strength of the counter-ions, pH environment, and the modifier 
contained in the mobile phase. 
Size-exclusion chromatography is usually applied in the separation of macromolecules 
according to their ability to penetrate into the pore of stationary material. The elution time 
of analyte is merely based on their size, but not molecular weight. The retention decreases 
as the size increases. 
Besides the aforementioned traditional chromatography, there are some modern 
approaches for improving chromatographic resolution and separation efficiency: ultra-
performance liquid chromatography (UPLC), monolithic chromatography, and hydrophilic 
interaction chromatography (HILIC). Underlying the same basic principle with RP-LC, 
UPLC utilizes column with sub-2 μm particle size and a system that can handle evaluated 
pressure. UPLC has a great advantage in resolution, sensitivity, and speed over 
conventional HPLC, and thus is considered as a better tool for high throughput analysis. 
Monolith column is packed with highly porous material, which is designed to handle fast 
flow rate and ensure sufficient surface for separation at the mean time. Consequently, the 
separation speed and sample throughput are significantly increased. HILIC is a valuable 
alternative to NP chromatography for very polar compounds because polar compounds are 
hardly retained and experience bad reproducibility when using NP chromatography. In 
addition, the large portion of organic mobile phase used for the HILIC elution increases 
the sensitivity when coupling MS with LC for detection. 
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In general, a sample is separated and analyzed by LC in the following sequence: the sample 
solution is injected through an injection port, and then delivered by the mobile phase by 
high-pressure pumps, and finally flowed into the column for retaining and further elution 
(Fig. 1.1).  
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Figure 1.1, The instrumentation setup for LC separation 
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The instrumentation design should consider the following issues: the high-pressure is 
generated when the solvents are pumped into the small particle filled stationary phase: the 
dead volume of connecting tubes, the injector, and the mixing valve should be minimized 
to prevent the reduction of analyte peak resolution; the sample residue on the tubing and 
injector should be avoided for carry-over issue in quantitative analysis.        
Recent bioanalytical technologies have been considerably expanded over the past decade 
for quantitative determination of small molecules and large molecules in biological 
samples accurately. The combination of high-performance liquid chromatography (HPLC) 
with tandem mass spectrometry (MS/MS) detection is considered as the preferred method 
for the quantitative determination of drugs and metabolites in biological fluids due to its 
high sensitivity, selectivity, and short analysis time [9-11]. In the pharmaceutical analysis, 
the hyphenated LC-MS is the most powerful technique because of the complex nature of 
the matrix (often plasma or urine) and the need for high sensitivity to observe 
concentrations after a low dose and a long time period [9, 12].  
The most common instrumentation used in this application is LC-MS with a triple 
quadrupole mass spectrometer with ESI or APCI interface. Tandem mass spectrometry is 
usually employed for added specificity [9].  
 
1.2.1.2. MS detection 
The general mechanism of MS detection is the analyte in liquid flow from the HPLC goes 
into three components of the mass spectrometer of ionization source in which the sample 
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is ionized, a mass analyzer in which the ions are separated and sorted according to their 
mass and charge ratio, and the detector which measures and detects the separated ions. The 
mass spectrometry is capable of not only indicating the presence of impurities but also able 
to give the molecular weights of underlying components and to distinguish between 
different molecules. 
HPLC/MS became a success with the introduction of atmospheric pressure ionization 
(API) ten years back that enables the MS analysis by generating ions in a stream of liquid 
after HPLC separation. The most widespread method for quantifying small molecules is 
quadrupole MS interfaced with a number of API sources such as electrospray ionization 
(ESI) or atmospheric pressure chemical ionization (APCI). These ionization sources 
convert the sample from liquid phase to gaseous state [9]. 
In the ESI source, a highly positive or negative voltage is applied to the end of a steel 
capillary probe, where the sample solution is introduced. In electrospray ionization, the 
analyte is introduced to the ion source in solution either from a syringe pump or as the 
eluent flow from liquid chromatography. The analyte solution flow passes through the 
electrospray needle that has a high potential difference (with respect to the counter 
electrode) applied to it (typically in the range from 2.5 to 4 Kv). This forces the spraying 
of highly charged fine droplets from the needle with a surface charge of the same polarity 
to the charge on the needle. After the solvent is further evaporated from these droplets, the 
droplet shrinks until it reaches the point that the surface tension can no longer sustain the 
charge at which point a coulombic explosion occurs and the droplet is diffused apart 
leaving the ions to enter to the mass analyzer. The process of ESI is shown in Fig.1.2. 
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Figure.1.2, The schematic diagram of ESI source 
 
 
 
 
 
 
 
 
13 
 
Unlike ESI, APCI evaporates the solvent by passing it through a heated tube where the 
high voltage is applied to the needle to generate a corona discharge and forming the plasma 
ions in the solvent. These solvent ions ionize the analyte molecules by means of gas phase 
reactions[9]. 
 Mass analyzers separate the ions according to their charge to mass ratio (m/z) by 
accelerating the ions with applying electric or magnetic field. Based on mass range limit, 
analysis speed, mass accuracy, and resolution, there are different types of mass analyzers 
are used. These include quadrupole MS, ion-trap MS, and time of flight (TOF) MS. 
The quadrupole mass analyzer [Fig.1.3] uses an electric field to select and separate the ions 
with a particular m/z. It consists of four parallel metal rods where adjacent rods have 
opposite voltage polarity applied to them. The voltage applied to each rod is the summation 
of a constant DC voltage and a varying radio frequency. 
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Figure.1.3, The operation of quadrupole mass analyzer 
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The electric force on the ions causes the ions to travel down the quadrupole between the 
rods. Only ions of a certain mass-to-charge ratio will reach the detector for a given ratio 
of voltages. Quadrupole analyzers have a limited m/z range, high sensitivity, and mass 
accuracy, but low percentage of ion transmission. Triple quadrupole (QqQ) mass analyzer 
consists of three quadrupoles arranged in a linear series. Precursor ions filtered in the first 
quadrupole (Q1) are dissociated in the collision cell (q2) in the presence of an inert gas 
such as Ar, He or N2 gas, and resulting selected fragments are filtered or scanned by third 
quadrupole (Q3) achieving high specificity. 
The quadrupole ion-trap mass analyzer employs similar principles as the quadrupole 
analyzer mentioned above, it uses an electric and magnetic fields for the separation of the 
ions by mass to charge ratios. The ion-trap MS (Fig.1.4) has the advantage of its high 
sensitivity and resolution. 
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Figure.1.4, A schematic way of an ion-trap mass analyzer 
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Time-of-flight (TOF) mass spectrometers use an electric field to accelerate gas phase ions 
toward a detector. The m/z of an ion will determine how long it takes to travel from the 
source to the detector, with low m/z ions traveling faster relative to high m/z ions. Several 
designs of TOF analyzers exist, some using a linear flight tube and others using one or 
more reflectrons that change the direction of ion flight and improve resolution or the ability 
to distinguish two m/z ratios from one another. TOF analyzers have an essentially 
unlimited m/z range and very high sensitivity, mass accuracy, and percentage of ion 
transmission, but a limited dynamic range. The modern MS instrument hybridizes different 
types of mass analyzers on one instrument to broaden the tandem mass spectrometry 
applications. 
The mass spectrometric detection of target analyte ions employs selected ion monitoring 
(SIM) and multiple reaction monitoring (MRM) scanning modes for LC-MS and LC-
MS/MS methods respectively. The SIM mode detection allows selecting the desired m/z 
value for the target analyte by the instrument.  This mode of analysis requires a single 
quadrupole and only the m/z of a precursor ion because no fragmentation is induced. 
Because only a limited mass-to-charge ratio range is transmitted or detected by the 
instrument, this operation typically results in significantly increased sensitivity.  
Comparing with SIM, MRM mode detection provides the unparalleled specificity because 
this analysis utilizes triple quadrupole mass analyzer to select and analyze a specific 
analyte. In MRM mode, two stages of mass filtering are employed on a triple quadrupole 
mass spectrometer. In the first stage, an ion of interest (the precursor) is preselected in Q1 
and induced to fragment by collisional excitation with a neutral gas in a pressurized 
collision cell (q2). In the second stage, instead of obtaining full scan MS/MS where all the 
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possible fragment ions derived from the precursor are mass analyzed in Q3, only a small 
number of sequence-specific fragment ions (transition ions) are mass analyzed in Q3. This 
targeted MS analysis using MRM enhances the lower detection limit as compared to full 
scan MS/MS analysis by allowing rapid and continuous monitoring of the specific ions of 
interest.  Particular precursor ions and product ions are selected for detection based on their 
unique pathways, MRM provides a great improvement in signal to noise ratio.  
  
1.2.2. Mobile phase optimization 
Mobile phase additives are often added in RP-LC for reproducible retention and the 
improvement of resolution and sensitivity when using MS as a detector. However, only 
volatile additives are compatible with LC-MS because the non-volatile buffers such as 
phosphates may clog the ionization source and cause signal suppression. In addition, some 
volatile additives help the retention but deteriorate the MS ionization. For example, 
trifluoroacetic acid (TFA) is commonly used as an ion-pairing agent for increasing the 
retention of polar compounds. Nevertheless, it is also reported to induce significant signal 
suppression for some negatively and positively charged compounds [13-15]. 
Besides the LC modifiers, the pH of the mobile phase also has a large impact on both 
retention and ionization. By adding volatile acids as formic acid, acetic acids, and their 
salts with ammonium in the mobile phase, the protonation of basic molecules under 
positive ionization mode is favored in acidic condition. Similarly, the deprotonation of 
some acidic molecules in negative-ion mode can increase the response by adding 
ammonium hydroxide as mobile phase additive. However, these conditions may cause an 
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adverse effect on retention if the hydrophobic interaction between analyte ions with the 
stationary phase is not sufficient [16]. In addition, the concentration of the additives is also 
critical since the MS response is reduced at high concentrations and lacks buffer capacity 
at low concentrations. To solve the dilemma between retention and ionization, the selection 
of mobile phase composition needs a careful consideration of all the characteristics of an 
individual analyte. 
1.2.2.1. Sample preparation   
Although LC is a powerful tool for separation, the sample pretreatment for a biological 
sample before injecting to LC-MS is essential for accurate and reproducible analysis. The 
biological samples matrices are very complicated with much higher content in plasma salts, 
and endogenous lipids than target analyte. The large protein content in plasma sample is 
problematic due to clogging of the column and reducing analytical efficiency. In addition, 
the endogenous interference and salts in most biological samples may suppress the 
ionization of analyte. 
Conventionally, the sample cleanup has been performed by protein precipitation (PPT), 
liquid-liquid extraction (LLE), and solid phase extraction (SPE). PPT is popular when 
handling plasma sample because it is simple and fast. But the major disadvantage for PPT 
is that residues consisted of salts and endogenous materials after the removal of proteins, 
which may greatly affect the MS detection. Besides the use of organic solvents for 
denaturing proteins, other PPT additives such as acids, metal ions, and salts were reported 
to improve the efficiency of protein removal and disrupt the protein-drug binding. 
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LLE is an efficient technique to separate analyte from sample matrices based on the 
different distribution in the water-immiscible organic phase and aqueous phase. It is 
successful in giving excellent sample cleanup. But the disadvantage for LLE include the 
relatively large sample and solvent consumption, possible formation of emulsion, and 
unsuitability for hydrophilic compounds. Based on the conventional LLE, the salting-out-
assisted-LLE is developed as a more convenient alternative by adding concentrated 
ammonium salt solution into a mixture of biological sample and water-miscible solvents. 
In this way, high-throughput LLE can be applied through the automation of the handling 
process in 96-well plate. 
The separation process of SPE method prior to sample analysis is similar to LC separation. 
The analyte is isolated relying on its affinity difference with the liquid sample solution and 
the solid SPE sorbents. Depending on the interaction of analyte and the selected solid 
phase, the SPE sorbents vary from polymer based ion-exchange materials to silica based 
materials. Typical SPE procedure start with the conditioning of the cartridge by a solvent 
or water. Then the sample is added onto the cartridge and the analyte interacting with the 
sorbent is retained. While the interferences are removed after rinsing the cartridge with 
buffer or solvent, the analyte can be eluted with an organic solvent and further concentrated 
by evaporation and re-constitution.   
  
1.2.2.2. HPLC separation 
Liquid chromatography is the basic separation technique for the separation of the analyte 
of interest from the components of the mixture. High-performance liquid chromatography 
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(HPLC) is the most widely used separation method in bioanalysis. The mechanisms of 
liquid chromatography are based on distribution and partition of analyte between liquid 
mobile phase and stationary phase. There are different types of chromatographic methods 
based on different types of stationary phases applied. These include ion-exchange 
chromatography (IEC), reversed-phase chromatography (RPLC), normal phase 
chromatography (NPLC), and size-exclusion chromatography (SEC) etc. 
Besides traditional HPLC, there are some modern approaches such as ultra-performance 
chromatography and hydrophilic interaction chromatography (HILIC) to improve the 
chromatographic separation efficiency and resolution. By using smaller particles, speed 
and peak capacity can be extended to new limits, termed Ultra Performance Liquid 
Chromatography (UPLC). This technique takes full advantage of chromatographic 
principles for separations using columns packed with smaller particles and higher flow 
rates for increased speed, with superior resolution and sensitivity over conventional HPLC 
by handling elevated pressure.  
All small molecule compounds and peptides are separated by RP-LC with a C18 column 
and mass spectrometric detection. A guard column is used to prevent the contamination 
from the injected biological samples and damage from the mobile phase additives. A 
successful quantitative LC-MS/MS method development requires three important 
interlinked methodologies: MS detection, chromatographic separation, and sample 
preparation. The steps involve in general method development process shown in Fig.1.5. 
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Several types of sample preparation methods are existed to extract the analyte from the 
biological matrices such as solid phase extraction (SPE), liquid-liquid extraction (LLE), 
and protein precipitation (PP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
 
 
 
 
Obtain the chemical structure 
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Develop MS detection 
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Figure.1.5, Method development workflow for small molecules 
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1.2.2.3. Matrix effect 
Matrix effect is one of the major issues encountered during LC-MS method development 
and validation. The phenomenon of matrix effect is observed when the ionization of analyte 
is suppressed or enhanced by the undetected co-eluting components from the biological 
matrix. The adverse results of matrix effect are reduced sensitivity for the detection and 
deteriorated precision and accuracy of the assay. According to the FDA guideline, it is 
required to assess the matrix effect when developing a reliable bioanalytical method. 
In order to quantitatively determine the absolute matrix effect, a useful strategy was 
proposed by matuszewski et al. [17]. The matrix effect is evaluated by comparing the signal 
response of analyte obtained from a neat solution with that from a post-extraction solution, 
in this way, two sets of samples are examined: one set is prepared by spiking standard 
analyte in neat solution and the other set is prepared by spiking standard analyte at the same 
concentration in the extracted solution of blank biological samples, which is termed as 
post-extraction solution. The difference of response from these two sets determines 
whether signal is suppressed or enhanced. More importantly, the relative matrix effect 
should be evaluated by comparing the response of analyte in post-extraction solution from 
different blank matrix sources.    
The post-column infusion of analyte is usually helpful to locate the co-eluting substances 
causing suppression in an LC run. A mixing tee is setup after the column elution and prior 
to MS ionization interface. The post-extraction of a blank biological matrix is injected into 
the LC system, and then eluted by the mobile phase from the column. At the matrix eluents 
mix with the analyte, which is infused constantly through an individual syringe pump. The 
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MS monitors the signal changes after the injection of post-extraction solution. The signal 
response of analyte should be expected to be steady in the absence of suppressing 
impurities. When the ion suppression or enhancement of analyte is present, the signal 
response will drop or increase at certain time points when interferences are eluted out, 
which can be easily observed on the chromatogram. In this way, the elution time of the 
ionization interferences and the extent of suppression or enhancement effect can be 
assessed through several continuous runs. The subsequent experimental design of analyte 
elution should avoid the co-elution with interferences.  
Matrix suppression is induced by different reasons ranged from endogenous compounds 
from inadequate sample clean-up, ion-suppression mobile phase additives, choice of 
ionization method, to sample storage conditions. One of the most extensively used and 
efficient method to solve matrix effect issue is the utility of stable isotope labeled (SIL) 
internal standard. Since the SIL internal standard has very similar chemical structure and 
properties compound to the analyte, the ionization suppression or enhancement effect on 
both compounds is expected to be the same level. However, the SIL internal standard is 
costly and sometime hard to obtain. It is also problematic for tracking the “cross talk” 
problem if the purity of SIL internal standard is not adequate. 
The matrix effect can also be minimized by improving the sample extraction method to 
remove the interferences. The endogenous compounds in biological samples have different 
polarity and thus are difficult to be completely removed by sample extraction methods. 
However, choosing the optimal sample preparation to reduce the amount of interferences 
is an efficient approach to ensure success in method development. Little et al. identified 
the phospholipids as a major contributor of matrix effect in blood and plasma by MS/MS 
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using different extraction methods [18]. Their results suggested that the 
glycerophosphocholines caused matrix effect in both positive and negative ionization, with 
lower effect for isocratic elution than gradient elution. As the effect of different sample 
pretreatment methods on matrix effect, it is reported that LLE had lower signal suppression 
compared to SPE, followed by the PPT extract, which usually contains the most 
endogenous residues.      
Alternatively, adjusting the chromatographic conditions is another approach to reduce or 
eliminate the matrix suppression. In the RP-LC separation, the suppression effect is often 
found in an early time of isocratic elution program and at the end of gradient elution during 
the post-column infusion. Therefore, it is wise to alter the elution of target analyte at other 
regions of the chromatogram where the matrix effect is the lowest. Some mobile phase 
additives such ad trimethylamine (TEA) and TFA can also induce matrix effect in LC-MS 
analysis. The strong ion-pairing ability of these additives helps trap very polar compounds 
in the column and reduce peak tailing, but it also masks the detection by neutralization the 
positive charge of analyte. The use of ammonium salts as a substitution or the choice of 
other column with different retention mechanism can relive this problem. 
In bioanalytical method development, matrix effect is more frequently reported in ESI 
interface MS than APCI since the ionization mechanisms are different in these two sources. 
In ESI, the analyte is charged when traveling in the electrical probe, then nebulized to small 
droplets, and at last evaporated in the gas phase. When the interfering compounds compete 
with the analyte for the surface charge, the charge transfer occurs if the interferences have 
higher proton affinity, causing the loss of charge for the analyte and the decrease of MS 
intensity. Compound to ESI, the APCI of analyte in liquid undergoes opposite sequence 
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for evaporation and ionization. The evaporation of liquid solvent takes place in the 
capillary before the ionization by charge transfer from the corona probe. 
In addition to the endogenous compounds causing matrix effect problems, other often 
neglected sources from the dosing vehicles and blood anticoagulant can also result in ion 
suppression. Dosing vehicles including propylene glycol, Tween 80, and hydroxypropyl-
β-cyclodextrin are often used in the pre-clinical PK studies. Undetected matrix effect in the 
post-dose samples would give underestimated drug concentration and generate PK results 
with large errors. It also has been suggested that heparin should be avoided for separating 
plasma from blood during sample handling. Sodium EDTA usually is preferred for 
anticoagulation in the PK and toxicokinetics studies for the prevention of matrix effect.   
 
1.3. Method validation 
The objective of any analytical method is to obtain an accurate, consistent and reliable 
measurement of the analyte. It is necessary to evaluate the performance of any analytical 
method once it has been developed. Method validation is used to judge the quality, 
reliability and consistency of the results obtained by an analytical method. Validation of 
analytical methods is required by most regulations and is considered a good analytical 
practice. Although there are several standards for method validation, FDA (U.S. Food and 
drug administration) and NTP (National Toxicology Program) guidelines are the most 
commonly accepted standards for method validation. According to these guidelines, there 
are several parameters that have to be considered when validating a bio-analytical method. 
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These parameters include sensitivity, selectivity, matrix factor, recovery, calibration curve, 
accuracy, precision, and stability. These parameters are described below in details.   
Selectivity is the ability of a method to differentiate and quantify an analyte in the presence 
of other components that may be present in the matrix. typical interfering substances in a 
biological matrix may include metabolites, impurities, detergents, decomposition products, 
xenobiotics and other endogenous matrix components. 
for non-MS analysis, analyses of blank samples from at least six sources of the matrix must 
be performed. for MS analysis, if non-isotopically labeled IS is used, matrix factor in six 
sources should be tested. in the case of an isotopically labeled is, matrix factor of an 
isotopically labeled IS should be close to unity. 
Sensitivity (lower limit of quantification, LLOQ) of an analytical procedure is the lowest 
amount of analyte in a sample that can be quantitatively measured with suitable accuracy 
and precision. 
The sensitivity of a method should be tested by analyzing at least 5 replicates of the sample 
at the LLOQ concentration on at least one of the validation days where the accuracy and 
precision should be lesser than or equal to 20%. 
Matrix factor is a measure of the effectiveness of the extraction, fractionation and GC 
analysis methods. the presence of a matrix effect may result in the ionization enhancement 
or suppression of analyte of interest. 
Matrix factor= (response in matrix) / (response in pure solution) x 100%  
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Matrix factor is calculated by comparing the ratio of the signals obtained by spiking the 
standards in the post-extraction matrix to that of the signals obtained in pure solution. to 
determine the matrix effect, five replicates of QC samples should be determined at three 
concentration levels (i.e. low, medium and high) of the calibration range. 
Recovery of a method is an evaluation of the effectiveness of the extraction methods. it is 
reported as the percentage of the analyte 
Recovery = (response of analyte in spiked analyte) / (response of analyte in extraction 
matrix) × 100 
Recovery is calculated by comparing the ratio of the signals obtained by spiking the analyte 
in the extracted matrix sample to that of the signals obtained by spiking the analyte in the 
post-extraction blank matrix. To determine recovery, five replicates of QC samples should 
be determined at three concentration levels (i.e. low, medium and high) of the calibration 
range. 
Calibration standards should be prepared in the same matrix as that of the real samples. 
In only some special cases where it is impossible to obtain a surrogate matrix or heavy 
isotope standards, calibration standards may be prepared in a solution matrix if and only if 
the matrix effect has been proven to be negligible. A calibration curve should include six 
to eight non-zero standards, one single blank (sample with internal standard] and one 
double blank [sample without internal standard). 
Accuracy of an analytical method is the closeness of the test results obtained to that of the 
true value of the analyte. The accuracy of a sample can be analyzed by measuring five 
replicates of the QC samples at three concentration levels (i.e. low, medium and high) in 
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the range of the calibration curve. The mean values of these measurements should be within 
15% of the actual value. Accuracy is expressed as percentage relative error (%RE) and is 
calculated by the following equation, 
%RE = [(measured – nominal)/nominal] x 100% 
Precision of an analytical method is the closeness of the measurements of the analyte 
obtained by multiple sampling of the same sample under the prescribed conditions. 
Precision of a sample can be analyzed by measuring five replicates of the QC samples at 
three concentration levels (i.e. low, medium and high) in the range of the calibration curve. 
The mean values of these measurements should be within 15% of the actual value. 
precision is expressed as percentage coefficient of variation (%CV) and is calculated by 
the following equation, 
%CV = (standard deviation/mean) x 100% 
accuracy and precision are further subdivided into intra and inter-run accuracy and 
precision. Intra-run accuracy and precision may be determined by measuring five parallels 
of the analyte (QC samples) on one of the validation days. these QC samples should include 
at least three concentration levels (low, medium, and high). 
Inter-run accuracy and precision may be determined by measuring five parallels of the 
analyte (QC samples) on five different validation days. these QC samples should include 
at least three concentration levels (low, medium, and high). 
Stability of an analyte is a measure of the bias in results obtained during a pre-selected time 
interval that can range from few hours to months. These studies provide important 
information on sample handling and storage. The most common stability studies include, 
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stock solution stability, freeze-thaw stability, post-preparative stability, short-term stability 
and long-term stability. For each stability study, at least two concentration levels (i.e. low 
and high) should be measured. at each concentration level, five parallel replicates should 
be determined. The signals of the analyte in the samples after incubation will be compared 
with those of the freshly made samples. The stability results are expressed as recovery of 
the analyte, and these indicate the degradation that can be seen by the signal loss. 
Stock, solution stability studies, should include a minimum of six hours’ study at room 
temperature. For each study at least two concentrations of the analyte should be studied. 
Bench top stability should be performed at ambient temperature conditions or at the 
temperature used for processing the samples as to cover the duration of time taken to extract 
the samples. This would typically include the time between 6 to 24 hrs. 
Post preparative stability is performed on the samples after they are processed and kept 
in an autosampler waiting for analysis. The study time should include a minimum time as 
to cover the total running time of a whole batch of samples. 
Freeze and thaw stability involves testing the analyte stability after three freeze and thaw 
cycles. The study should include at least five replicates at each of the low and high 
concentrations. for each cycle, samples should be stored and frozen to the intended storage 
temperature (i.e. -20 °c or -80 °c) for 12-24 hours and thawed unassisted to room 
temperature. 
Short-term stability studies are carried out at room temperature. Five aliquots each of the 
low and high QC concentrations are spiked into the biological matrix and left on the bench 
top and kept at this temperature from 4 to 24 hours and analyzed. 
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Long term stability studies are carried out at a desired storage place such as a refrigerator 
(4 °c) or in a freezer (-20 or -80 °c). In long-term stability studies, the storage time should 
exceed the time between the date of first sample collection and the date of the last sample 
analysis. It is determined by storing five aliquots of each of the low and high concentrations 
under the same conditions as the study samples. 
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CHAPTER II 
 
A RAPID AND SENSITIVE LC-MS/MS METHOD FOR QUANTIFICATION OF 
A NOVEL ANTITUMOR AGENT, IN RAT PLASMA 
 
2.1. Introduction of anti-cancer agent CSUOH0901 
CSUOH0901 {benzo [1, 3] dioxole-5-carboxylicacid [3-(2, 5-dimethylbenzyloxy)-4-
(methanesulfonylmethylamino)-phenyl] amide} (NSC751382) (Fig. 2.1A) [1] is a novel, 
second generation anti-cancer agent derived from Nimesulide, which can inhibit 
cyclooxygenase-2 (COX-2) (Fig. 2.1C). In cancer therapy, Nimesulide showed 
hepatotoxicity on long term usage and required higher concentrations to inhibit COX-2 
activity [2]. This led to the development of CSUOH0901, a Nimesulide derivative, which 
exhibited very promising anticancer activities by interacting with tubulin and Hsp27 
proteins, which are important to cancer cell proliferation. It was evident that CSUOH0901 
inhibited the proliferation of cancer cells of lung, breast, colon, CNS, ovary, renal and 
37 
 
prostate cancer with IC50 of 0.1-0.5 µM, which is 10 fold more active than JCC76 {N- (3-
(2,5-dimethylbenzyloxy)-4- (methylmethylsulfonamido) phenyl) 
cyclohexanecaboxamide} (Fig. 2.1B) [3] and 1000 fold more potent than nimesulide [1].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
 
 
     [A] 
 
   
      [B]           [C] 
Figure. 2.1, The chemical structures of CSUOH0901 (A), internal standard JCC76 
(B), and nimesulide (C). 
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Recent docking studies in SKBR-3 breast cancer cell lines [3, 4] revealed that CSUOH0901 
interacted with both α-tubulin and β-tubulin in the colchicine pocket and disorganized 
microtubules. Additionally, interaction of heat shock protein 27 (Hsp27) [5] with 
CSUOH0901 inhibited the phosphorylation of Hsp27, leading to cell apoptosis.  Hsp27 is 
a stress protein that is expressed when cells are stimulated by heat [6-8], radiation [9], 
chemotherapeutic drugs [10], or other agents [11]. A recent study showed that cancer cells 
with HSP27 overexpression were resistant to chemotherapeutic drugs [12-15]. Antisense 
to inhibition of the HSP27 gene decreased cellular resistance to chemotherapy as well as 
to heat shock [16]. Other studies have suggested that HSP27 prevents cancer cells from 
apoptosis and dramatically enhances their tumorigenicity [17-20]. Mass spectrometric 
studies revealed that tubulin and Hsp27 proteins are the most prevalent targets of 
CSUOH0901. Recent in vivo studies demonstrated that CSUOH0901 significantly 
decreased the size of the HT29 tumor in a Xenograft model compared to the control group, 
suggesting the low toxicity and high potency in vivo [2]. 
Clearly, CSUOH0901 is a very promising anticancer drug candidate and will be further 
studied. However, to date, no LC-MS/MS method has been developed for the 
quantification of CSUOH0901. Therefore, a simple and accurate method to quantify 
CSUOH0901 is needed which will be essential to the future pharmacological and 
toxicological studies of CSUOH0901. In this work, a rapid and sensitive LC-MS/MS 
method was developed and validated for quantitative determination of CSUOH0901 in rat 
plasma. We demonstrated that the method developed was fast, sensitive, and specific for 
quantifying CSUOH0901 in plasma which can be used in pharmacological studies. 
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2.2. Experimental 
2.2.1. Chemical and reagents  
CSUOH0901 and JCC76 (Internal standard) were synthesized and purified according to 
the previously published procedures [1, 3]. HPLC grade methanol and acetonitrile were 
purchased from Pharmco-Apper (Philadelphia, Pennsylvania, USA). Formic acid, 
Ammonium formate, and ammonium acetate were purchased from Sigma-Aldrich 
Chemical Company (Allentown, Pennsylvania, USA). Dimethyl sulfoxide was obtained 
from Fisher Scientific (Pittsburgh, Pennsylvania, USA). Deionized water was generated 
from Barnstead Nano pure water purification system from Thermo Scientific (Waltham, 
Massachusetts, USA). Sprague-Dawley rat plasmas K2 with specific lot numbers (10577-
01, 02, 03, 04, 05, and 06) were purchased from Innovative research (Novi, Michigan, 
USA). 
 
2.2.2. Calibration standard and quality control samples  
2.2.2.1. Preparation of stock and working solutions  
The stock solutions of CSUOH0901 and JCC76 (IS) were prepared in dimethyl sulfoxide 
(DMSO) at 1 mg/ml and stored at -20 oC. A set of CSOH0901 working solutions of 10, 20, 
50, 150, 400, 1000, and 2000 ng/ml were prepared by serial dilution of the stock solution 
with DMSO. The working solution of JCC76 (IS) was obtained by diluting the stock 
solution with DMSO to give a concentration of 150 ng/ml. 
 
41 
 
2.2.2.2. Preparation of calibration and quality control plasma samples  
The calibration plasma solutions were prepared by spiking 10 µl of CSUOH0901 working 
solutions in 200 µl of blank plasma (mixture of 6 lots) to give drug concentrations of 0.5, 
1.0, 2.5, 7.5, 20, 50, and 100 ng/ml. The LLOQ and QC standards were prepared in a similar 
way at 0.5, 1.25, 10, 80 ng/ml, representing the lower limit of quantification (LLOQ), low 
QC (LQC), middle QC (MQC), and high QC (HQC) respectively. The QC and calibration 
samples were frozen at -20 oC overnight, and then treated by the following sample 
preparation procedure and subjected to LC-MS/MS analysis. 
 
2.2.3. Sample extraction  
Plasma samples were removed from -20 oC freezer, and thawed to room temperature. 
Single and double blanks were prepared by spiking 10 µl of acetonitrile in 200 µl of rat 
plasma. Then 10 µl of IS working solution was spiked in all calibration, QC solutions and 
single blank, except in double blank and vortexed immediately for 30 sec. The above-
prepared samples were deproteinized by adding 800 µl of acetonitrile and sonicated for 15 
minutes followed by centrifugation at 13,000 × g for 15 minutes. The supernatants were 
transferred into auto sampler vials for LC-MS/MS analysis.  
 
2.2.4. LC-MS/MS analysis 
LC-MS/MS analysis was conducted using 5500 QTRAP triple quadrupole, tandem mass 
spectrometer (AB Sciex, Toronto, Canada) with electrospray ionization (ESI) source 
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(Framingham, Massachusetts, USA) interfaced with high performance liquid 
chromatography (HPLC, Shimadzu, Columbia, Maryland, USA) with two LC-30 AD 
pumps, DUG-20A3R inline degasser, a SIL-30 AC auto sampler, CBM-20A controller and 
CTO-10AVP column oven (Shimadzu, Tokyo, Japan).  Analyst software, version 1.5.2 
(AB Sciex) was used to control all the parameters of tandem mass spectrometer and HPLC. 
A Luna C18 [2] HPLC column (50 × 2.0 mm 5 micron) with a C18 security guard cartridge 
from Phenomenex (Torrance, California, USA) was used for the chromatographic 
separation of the supernatants from the deproteinized samples. An optimized gradient flow 
of mobile phase A: 5mM ammonium formate in 2% Methanol and mobile phase B: 5mM 
ammonium formate in 90% Methanol at a flow rate of 0.2 ml/min was developed. The 
column was equilibrated with the mobile phase for 10 min and the run time was 8 minutes 
for each run with 10 µl injection volume. The positive electrospray ionization (ESI) mode 
was selected and the MRM (multiple reaction monitoring) function was used for 
quantification, with the transitions set at m/z 483.2 → 404.3 for CSUOH0901 and m/z 
445.3 → 366 .3 for JCC76 (IS) (Fig. 2.2) respectively. The dwell time for each MRM 
transition was set at 120 ms. Source dependent parameters were optimized by flow infusion 
analysis: Nebulization gas [30], heating gas [30], curtain gas [40], ion spray voltage 
[5000ev] and temperature [450ºC]. Compound dependent parameters were manually 
optimized as following: Declustering potential [180], Entrance potential [10], Collision 
Energy [20], Cell Exit Potential [12]. 
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Figure 2.2, Precursor/product ion spectra and proposed fragmentation pathways for 
internal standard JCC76 (A) and analyte CSUOH0901 (B). 
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2.2.5. Analytical method validation 
A full method validation was performed using rat plasma according to the currently 
accepted FDA Bio analytical method guidelines [21] and also other references [22, 23]. 
The entire method was validated for precision, accuracy, linearity, selectivity, extraction 
recovery, the lower limit of quantification (LLOQ), matrix effect and stability studies. 
 
2.2.5.1. Calibration curve, linearity and sensitivity  
Seven CSUOH0901 plasma calibrators at the concentrations of 0.5, 1.0, 2.5, 7.5, 20, 50, 
100 ng/ml, double blank and single blank (only JCC76 internal standard) were selected to 
establish a calibration curve. The weighed linear regression, 1/x as weighing factor was 
used to calculate the slope and correlation coefficient of the calibration curve. The LLOQ 
was defined as the concentration with precision (%CV) < 20%. 
 
2.2.5.2. Accuracy and precision  
Intra-assay and inter-assay precision and accuracy studies were performed using three QC 
standards LQC, MQC, and HQC at 1.25, 10 and 80 ng/ml with five replicates (n = 5). Intra-
assay and inter-assay precisions determined as % coefficient variance (%CV), and 
accuracies were calculated by comparing experimentally determined concentrations with 
the spiked values. Therefore, accuracy (%) = (experimental concentration) / (spiked 
concentration) x 100. 
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2.2.5.3 Recovery and matrix effect 
The absolute extraction recovery was determined by comparing the peak areas of 
CSUOH0901 in QC samples at 1.25, 10, and 80 ng/ml (CSUOH0901 added prior to 
deproteinization), to those of post extraction samples (CSUOH0901 added after 
deproteinization) of corresponding concentrations. The relative recovery was determined 
by comparing peak area ratio of CSUOH0901 and IS (JCC76) spiked in plasma before 
extraction with that in post extraction spiked samples. 
The absolute matrix effect was calculated by comparing the peak areas of post extraction 
blank plasma samples spiked with CSUOH0901 (1.25, 10, and 80 ng/ml) to those of 
corresponding standard solutions at equivalent concentrations. The relative matrix effect 
was calculated by comparing the peak area ratio of CSUOH0901 and IS (JCC76) spiked in 
the blank plasma post extraction solution with that in the standard solution. 
 
2.2.5.4. Stability studies 
2.2.5.4.1. Effect of freeze-thaw on CSUOH0901 in plasma 
Two QC samples of 1.25 and 80 ng/ml concentrations were selected to verify their stability. 
Stability test for CSUOH0901 in plasma was studied after three freeze thaw cycles over a 
three-day period.  
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2.2.5.4.2. Short term and long term stability studies of analyte in plasma 
The Stability studies of CSUOH0901 in rat plasma were performed using two QC standards 
(1.25 and 80 ng/ml), which were kept under different storage conditions: 10 hours at room 
temperature and 6 months at -20 oC, before and after sample extraction.   
 
2.2.5.4.3. Stability of analyte in stock solutions 
The Stability studies of stock solutions and working solutions of CSUOH0901 and internal 
standard (JCC76) were also evaluated. The stock solutions of analyte were stored at -20 oC 
for 7 months. Two QC standards of concentrations 1.25 and 80 ng/ml were prepared from 
both the stored and fresh stock solutions and the experimentally determined concentrations 
of CSUOH0901 were compared (n=3 for each sample). 
 
2.3. Results and discussion 
2.3.1. Optimization of mass spectrometric conditions for MRM quantitation 
Positive ionization mode was selected to detect and optimize the MS parameters for the 
detection of both CSUOH0901 and JCC76 (internal standard). It was found that the 
standard CSUOH0901 and JCC76 solutions prepared in methanol-water (9:1, v/v) yielded 
higher intensity when compared to the solutions prepared in acetonitrile-water (9:1, v/v). 
Fragmentation lead to the formation of daughter ions in the product ion scan mode (Fig. 
2.2). Based on the fragmentation study, the MRM transitions of m/z 483.2 → 404.3 for 
CSUOH0901 and 445.3 → 366.3 for JCC76 were selected for quantification, as these 
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product ions yielded strong signals. The highest MS signal was obtained by fine-tuning 
collision energy, spray voltage, and ion source temperature.  
 
2.3.2. Optimization of HPLC conditions 
To overcome the irreproducibility and matrix effect problems associated with the isocratic 
flow, a gradient flow of mobile phase A: 5mM ammonium formate in 2% Methanol and 
mobile phase B: 5mM ammonium formate in 90% Methanol with 0.2 ml/min flow rate was 
employed. This gradient flow improved the sensitivity and signal-to-noise ratio with a total 
run time of 18 minutes. High concentration of methanol was used to elute CSUOH0901 
from C18 column, due to its low solubility in water with predicted logD value of 4.86. The 
intensity of CSUOH0901 has increased two folds when 5mM ammonium formate buffer 
was used in the mobile phases and the retention times were found to be around 5.09 min 
for CSUOH0901 and 5.58 min for JCC76 (IS) (Fig. 2.3B). 
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Figure 2.3, [A] MRM chromatograms of blank rat plasma in both IS and analyte 
windows [B] IS JCC76 (10 ng/ml, 5.58 min) and CSUOH0901 at LLOQ level (0.5 
ng/ml 5.10 min). 
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2.3.3. Linearity, sensitivity, selectivity and LLOQ 
The Calibration curve for CSUOH0901 in plasma was linear in the range of 0.5 – 100 
ng/ml. Linearity results showed the quadratic fit for CSUOH0901 with a seven-point 
calibration curve of concentrations 0.5, 1.0, 2.5, 7.5, 20, 50, and 100 ng/ml including 
double blank and single blank (only JCC76 internal standard) plasma samples. An excellent 
linearity was obtained with the correlation coefficient of 0.9996 and the linear regression 
equation was y= 0.073x -0.0085. This method exhibited high selectivity with no interfering 
peak in six different blank plasma samples from different sources. The LLOQ was found 
to be 0.5 ng/ml, where the signal intensity was twenty folds higher than the blank signal 
(Fig. 2.3). The lowest concentration in a calibration curve (LLOQ) was quantified with the 
accuracy and precision within 15% (Table 2.1). 
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Table 2.1, Accuracy and precision of CSUOH0901 calibration standards [n=5] over 0.5 – 100 ng/ml 
Nominal Concentration        Determined Concentration                   Accuracy                          Precision 
           [ng/ml]                                    [ng/ml]                               [%RE]                           [%CV] 
0.5 
1 
2.5 
7.5 
20 
50 
100 
0.49±0.01 
0.90±0.09 
2.58±0.08 
7.23±0.27 
20.42±0.42 
49.14±0.86 
97.30±2.70 
-2.0% 
-10.0% 
3.2% 
-3.6% 
2.1% 
-1.7% 
-2.7% 
4.5% 
6.0% 
6.7% 
11.0% 
1.7% 
1.6% 
2.2% 
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2.3.4. Accuracy and precision 
Intra-assay and inter -assay accuracies of the validated method ranged from 1.9 to 11.2% 
and 0.5 to 11.2%, respectively. The Intra-assay and inter –assay precision values ranged 
from 1.8 to 2.9% and 4.5 to 5.5%, respectively. The inter and intra-assay accuracy and 
precision of the QC samples are depicted in Table 2.2.  
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Table 2.2, Inter and intra-assay accuracy and precision of CSUOH0901 in rat plasma 
Intra- assay  Inter- assay 
Normal 
[ng/ml] 
Determined 
[ng/ml] 
Accuracy 
[%RE] 
SD 
Precision 
[%CV] 
 
Determined 
[ng/ml] 
Accuracy 
[%RE] 
SD 
Precision 
[%CV] 
1.25 
10 
80 
1.39 
10.26 
78.52 
11.2% 
2.6% 
-1.9% 
0.04 
0.18 
1.44 
2.9% 
1.8% 
1.8% 
 
1.39 
10.35 
79.58 
11.2% 
3.5% 
-0.5% 
0.07 
0.46 
4.36 
5.0% 
4.5% 
5.5% 
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2.3.5. Extraction recovery and matrix effect   
The absolute recovery of the extraction method was found to be (104.0%, 105.0%, and 
104.0%) of the QC standards at 1.25, 10, and 80 ng/ml, and the relative recovery of the 
extracted method was found to be (99.9%, 96.1% 97.7%) of the QC standards at 1.25, 10, 
and 80 ng/ml, respectively as indicated in Table 2.3. Absolute matrix effect for each other 
plasma samples at 1.25, 10, and 80 ng/ml was 5.5%, 8.1%, and 9.9%, and relative matrix 
effect was 2.6%, 5.1% and 12.4% indicating the minimal matrix effect. Hence, the protein 
precipitation technique for sample preparation was found to be effective, as it not only 
extracted the analyte and internal standard well but also removed impurities causing 
interferences from the sample matrix.  
Performing multiple reaction monitoring (MRM) confirmed the absence of significant 
matrix effect by comparing the peak areas ratio of CSUOH0901 MRM transitions (MRM1: 
m/z 483.2 → 404.3 and MRM2: m/z 483.2 → 119.0) for the spiked rat plasma samples 
with the average peak area ratio for seven calibrators.  
MRM Ratio = Peak area MRM1/ Peak area MRM2                               [1] 
The average MRM ratio of the seven calibrators was found to be 1.5 ± 1.9 (± SD). This 
confirmed the absence of matrix effect in the plasma samples and that they are in the 
acceptable range. 
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Table 2.3, Absolute and relative matrix effect and recovery of CSUOH0901 in rat plasma 
 
 
 
Concentration of 
QC samples[ng/ml] 
Matrix effect  Recovery 
Absolute Relative  Absolute Relative 
1.25 
10 
80 
5.5% 
8.1% 
9.9% 
2.6% 
5.1% 
12.4% 
 
104.0% 
105.0% 
104.0% 
99.9% 
96.1% 
97.7% 
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2.3.6. Stability 
CSUOH0901 was found to be stable for at least 8 hours at room temperature (bench top) 
and for 10 hours when post extracted at room temperature and the results were summarized 
in Table 2.4, The recovery of CSUOH0901 was found to be 112.0% at LQC and 104.5% 
at HQC levels after 3 freeze-thaw cycles. Stability studies of stock solutions and working 
solutions of CSUOH0901 and internal standard (JCC76) were performed, respectively by 
storing them at -20 oC for at least 6 months. The analyte and the internal standard were 
found to be stable in stock solutions and the results are summarized in Table 2.5. 
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Table 2.4, Stabilities of CSUOH0901 under various conditions  
 
 
 
 
 
 
 
 
 
Stability 
Concentration 
[ng/ml] 
Recovery 
% 
Bench top[8hr] 
At room temp 
1.25 112.0% 
80.00 99.1% 
Freeze thaw [3 cycles] 
1.25 112.0% 
80.00 104.5% 
Post extraction 
[10hrs] at room temp 
1.25 106.4% 
80.00 97.8% 
57 
 
 
 
 
Table 2.5, Stabilities of CSUOH0901 and JCC76 Stock solutions after storage at -20 0C for 6 months  
 
 
 
Type of Solutions Concentration Recovery [%] 
CSUOH0901 Stock solution 1 mg/ml 111.8% 
JCC76 Stock solution 1 mg/ml 106.0% 
CSUOH0901 Working Solution 
25 ng/ml 99.6% 
1600 ng/ml 105.0% 
JCC76 Working Solution 150 ng/ml 124.6% 
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2.4. Conclusion  
In conclusion, a highly sensitive LC-MS/MS method for the quantitation of CSUOH0901 
in rat plasma was developed and validated for the first time. The method developed has a 
short run time of 18 minutes employing a simple one step sample preparation. The accuracy 
and precision are lower than 10% and the LLOQ is as low as 0.5 ng/ml. The results from 
the validation studies illustrated that this method can be used to determine the 
pharmacological and toxicological profiles of CSUOH0901 in rats in the near future.   
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CHAPTER III 
 
A SIMPLE AND RAPID LC-MS/MS METHOD FOR THE DETERMINATION 
OF BMCL26, A NOVEL ANTI-PARASITIC AGENT, IN RAT PLASMA 
 
3.1. Introduction 
 
Human African trypanosomiasis, also known as sleeping sickness, is a vector-borne 
parasitic disease and also a serious health threat to a large number of people living in sub-
Saharan Africa where health systems are least effective [1-3]. Trypanosoma brucei 
gambiense (T. b. gambiense) and Trypanosoma brucei rhodesiense (T. b. rhodesiense) are 
the etiological parasites of sleeping sickness in humans. These parasites live and grow 
extracellularly in the blood and tissue fluids of humans or cattle, and are transmitted among 
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hosts by tsetse flies (Glossina spp). The disease is always caused by an infected tsetse fly 
bite and moves through an initial stage, where trypanosomes proliferate in the bloodstream 
and lymphatic system. The disease can then progress; the trypanosomes will cross the 
blood-brain barrier and invade the central nervous system eventually. During the second 
stage, patients will present a variety of neurological symptoms and often exhibit an 
alteration of the circadian sleep/wake pattern. That is also how the disease is named 
“sleeping sickness”. Without effective treatment, the disease will lead to coma and 
ultimately death. If the patients do not receive treatment before the onset of the second 
phase, neurological damage caused by the parasites is irreversible even after treatment [3, 
4]. 
The current chemotherapy of the human trypanosomiasis relies on only four drugs 
including Suramin, Pentamidine, Melarsoprol and Eflornithine [5]. The main drawbacks 
of these drugs are: 1) high toxicity to the hosts, which is mainly due to their poor selectivity 
to the parasite cells than the mammalian cells; 2) these agents have to be administered via 
intramuscular or intravenous injections; 3) they have very narrow anti-trypanosomiasis 
spectrum; and 4) treatment using these drugs needs the high cost of hospitalization. Overall, 
these drugs are not successful in the treatment of the disease, and there is a general lack of 
effective, inexpensive chemotherapeutic agents for the treatment of human African 
trypanosomiasis. Clearly, improved chemotherapeutics with better selectivity to the 
trypanosomes are needed to effectively treat this disease [4-6].  
Tubulin-containing structures are important for many important cellular functions, 
including chromosome segregation during cell division, intracellular transport, 
development and maintenance of cell shape, cell motility, and distribution of molecules on 
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cell membranes [7]. Tubulin is a very attractive target in anti-cancer drug discovery field, 
and several successful tubulin binders are the first line chemotherapeutic agents in the 
clinic [8]. Tubulin also plays an essential role during trypanosome cell division. The fast 
population doubling rate of trypanosomes makes them highly dependent on tubulin 
polymerization/depolymerization [9]. More importantly, tubulin is very critical for the 
trypanosome locomotion, which is an essential function for trypanosomes to survive. 
Tubulin inhibitors not only block the T. brucei cell division but will also affect the 
locomotion function of the flagellum and lead to cell death [10]. These factors indicate that 
there are potential advantages of tubulin inhibitors for the treatment of trypanosomiasis.  
Tubulin is a highly conserved protein. Examination of tubulin sequences from mammalian 
cells and yeast cells reveals 70% to 90% identity. However, differences in susceptibility to 
antimitotic agents are known to exist between tubulins from different organisms, 
suggesting that differences in tubulin structures exist among different species [11]. Based 
on the differences of tubulin in T. brucei and mammalian cells, it is highly expected that 
selective tubulin inhibitors could be developed. Some microtubule-disrupting herbicides 
such as phosphoric thioamide herbicide amiprophos-methyl (APM) and dinitroaniline 
herbicides exhibit activity against protozoan parasites by aiming tubulin as the molecule 
target [11-15]. Research has been done to optimize these compounds to generate more 
potent and selective tubulin inhibitors for T. brucei [11]. Webovertz’s group successfully 
developed several drug candidates showing promising in vitro anti-parasite activity and 
selectivity. However, these compounds did not show good in vivo potency due to the poor 
stability [16]. Nevertheless, these investigations demonstrated the feasibility to generate 
selective tubulin inhibitors as anti-trypanosomal agents.  
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We have developed a class of tubulin inhibitors as anti-cancer agents [17, 18]. These 
compounds share the same core scaffold, and bind to a colchicine-binding domain on 
tubulin [17]. Since there is the difference between mammalian and T. brucei tubulin, 
selective tubulin inhibitors for T. brucei might be identified within our tubulin inhibitor 
library. We performed T. brucei cell growth inhibition assay with our compounds, and 
some compounds exhibited a very specific inhibitory effect on T. brucei growth, with 
selectivity index (IC50 inhibiting human cancer cell growth/IC50 inhibiting T. brucei cell 
growth) being 5 or more. Compound BMCL26 is identified to be a potential drug 
candidate. It showed activity against T. brucei cell proliferation with an IC50 of 1.62 µM 
but inhibited mammalian cell growth with an IC50 of 55.35µM [19]. The selective index 
is about 34. In addition, the IC50 to inhibit T.brucei proliferation is at low micromole level 
that is reachable in blood. The drug may have potential in vivo activity. It is necessary to 
develop and validate a method to determine the blood drug concentration of BMCL26 for 
the future pharmacokinetic investigation for this compound. Hence, we focus on the LC-
MS//MS method development for compound BMCL26 in the current study.  
 
3.2. Experimental 
3.2.1. Chemicals and reagents 
BMCL26 and JCC76 (Internal standard) were synthesized and purified according to 
previously published procedures [19, 20] (Fig. 3.1). Methanol (HPLC grade) and 
acetonitrile were from Pharmco-Apper (Philadelphia, Pennsylvania, USA). Formic acid 
and ammonium acetate (analytical grade) were purchased from Sigma-Aldrich Chemical 
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Company (Allentown, Pennsylvania, USA). Deionized water was obtained using a 
Barnstead Nano pure water purification system with a Nanopure Diamond Pack Organic 
free DI cartridge from Thermo Scientific (Waltham, Massachusetts, USA). Six individual 
lots of rat plasma (Sprague-Dawley rat plasmas K2) were obtained from Innovative 
Research (Novi, Michigan, USA). 
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      [A] 
 
      [B] 
 
Figure 3.1, The chemical structures of JCC76 (A), analyte BMCL26 (B). 
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3.2.2. Calibration standards and quality-control samples 
3.2.2.1. Preparation of stock and working solutions  
A set of BMCL26 working solutions containing 10, 20, 50, 150, 400, 1000 and 2000 ng/mL 
were prepared by serial dilution using methanol and 1 mg/mL stock solution. The 150-
ng/mL working solution of JCC76 (IS) was diluted from a stock solution of 1 mg/mL in 
methanol. Stock solutions and working solutions were stored at – 20 0 C and 4 0 C. 
 
3.2.2.2. Calibration and preparation of quality-control (QC) plasma samples  
Calibration plasma samples were prepared by spiking 10 µl of corresponding BMCL26 
working solutions in 200 µl of rat plasma (mixture of 6 lots) with drug concentrations of 
0.5, 1.0, 2.5, 5, 12.5, 25, 50, and 100 ng/mL. QC samples at three concentrations, 1.25 
(low), 10 (mid) and 80 (high) ng/mL, were prepared by adding 10 μL of the appropriate 
BMCL26 working solution and 200 μL of drug-free plasma. Calibration and QC samples 
were frozen at -20 0 C overnight and then treated using the following sample preparation 
procedure before LC-MS/MS analysis. 
 
3.2.3. Sample extraction 
QC samples and blanks were removed from the -20-0C freezer and thawed to room 
temperature. Ten µl of JCC76 working solution were spiked into each 200-μL aliquot of 
plasma calibrators/QCs/blanks, excepting the double blank, into which 10 μL of 
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acetonitrile was added. The solutions were then vortexed immediately for 30 secs, after 
which each sample was deproteinized by adding 800 µl of 0.1% formic acid in acetonitrile, 
sonicating for 15 minutes, and centrifuging at 13,000 × g for 15 minutes. The supernatants 
were then transferred into auto sampler vials for LC-MS/MS analysis.  
 
3.2.4. LC-MS/MS analysis 
LC-MS/MS analysis was performed using a 5500 Q-TRAP triple quadrupole, tandem mass 
spectrometer (AB Sciex, Toronto, Canada) coupled with an electrospray ionizer (ESI) 
operated in negative ion mode (Framingham, Massachusetts, USA) and interfaced with 
high performance liquid chromatography (HPLC, Shimadzu, Columbia, Maryland, USA) 
system that uses auto-sampling and online vacuum degassing.  All data acquisition and 
processing were conducted using Analyst software, version 1.5.2 (AB Sciex). 
Analytical separation of BMCL26 was achieved using a Luna C8 [2] HPLC column (50 × 
2.0 mm, 5 microns) with a C8 security-guard cartridge from Phenomenex (Torrance, 
California, USA). Mobile phase A contained 50 μM ammonium acetate in 2% Methanol, 
and mobile phase B contained 50 μM ammonium acetate in 90% Methanol. Sample 
aliquots of 5 μl were injected onto the column and eluted via the following gradient flow: 
0-0.6 min, 70% B, 1.6 min, 90% B, 7.5 min, stop (see Table 3.1). The column was 
equilibrated for 0.5 min before each run. Negative electrospray ionization (ESI) mode was 
selected, and the MRM (multiple reaction monitoring) function was used for quantification, 
with the transitions set at m/z 573.3 → 493.2 for BMCL26 and m/z 443.2 → 79.1 for 
JCC76 (IS) (Fig. 3.2), respectively. The following ion-source-dependent parameters were 
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used: nebulization gas [30], heating gas [30], curtain gas [35], ion spray voltage [-4330ev] 
and temperature [500ºC]. Compound-dependent parameters were manually optimized as 
follows: Declustering potential, -40; entrance potential, -10; collision energy and cell exit 
potential for both the analyte and internal standard, -30, -100, -13, and -9. 
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Table 3.1, HPLC gradient program 
Minutes Event parameters 
0 - 0.6 B% 70 [isocratic] 
0.6 – 1.6 B% 70 - 90 [liner] 
0 – 3.5 Total flow 0.25 ml/min 
3.5 – 3.7 Total flow 0.25 - 0.6 ml/min 
1.6 – 5.5 B% 90 [isocratic] 
5.5 – 5.6 B% 90 – 70 [liner] 
3.5 – 5.9 Total flow 0.6 ml/min 
5.9 – 6.0 Total flow 0.25 – 0.6 ml/min 
5.6 – 7.5 B% 70 [liner] 
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Figure 3.2, Precursor/product ion spectra and proposed fragmentation pathways for 
internal standard JCC76 (A) and analyte BMCL26 (B). 
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3.2.5. Analytical method validation  
The LC-MS/MS assay was fully validated according to the Food and Drug Administration 
(FDA) Bioanalytical Method Guidelines [21] and other references [22-24]. The entire 
assay was validated for linearity, accuracy, precision, selectivity, extraction recovery, 
matrix effect, and stability. 
 
3.2.5.1. Linearity and calibration  
Eight concentrations of BMCL26 (0.5, 1.0, 2.5, 5, 12.5, 25, 50, and 100 ng/mL) were 
selected for the plasma calibration curve (n=2 for each of the eight calibrators, average for 
each calibrator plotted). A weighed linear regression, using 1/x as the weighing factor, was 
used to calculate the slope and correlation coefficient of the calibration curve. 
 
3.2.5.2. Accuracy and precision 
To determine the Intra- and inter-day accuracy and precision of the assay, we tested five 
replicates of BMCL26 at the LQC, MQC, and HQC using 1.25, 10 and 80 ng/mL. Intra-
assay and inter-assay precisions were defined as relative standard deviations (RSD) 
between replicate measurements. Accuracies were calculated using the following formula: 
accuracy (%) = (experimental concentration - spiked concentration) / (spiked 
concentration]) x 100. The criteria for data acceptability included accuracy and precisions 
within ± 15% of the nominal value and the RSD. 
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3.2.5.3. Extraction recovery and matrix effect  
The extraction recoveries and matrix effects of BMCL26 for three concentrations of QC 
samples (low, 1.25 ng/mL; medium, 10 ng/mL; and high, 80 ng/mL) were determined by 
comparing peak areas of analyte-spiked plasma aliquots before extraction to peak areas of 
analyte-spiked solutions extracted from blank plasma and comparing the response of 
solutions spiked with analyte after extraction to the response of analyte dissolved in the 
mobile phase. 
 
 3.2.5.4. Stability studies 
The stabilities of BMCL26 in rat plasma samples were determined using two distinct QC 
standards (1.25 and 80 ng/mL), which were tested after 8 hours at room temperature and 
after two months at – 20 0C; freeze-thaw stabilities were determined using three freeze-
thaw cycles over a three-day period. Short-term stabilities were also determined for post-
preparation QC standards stored at room temperature for 10 hours. The QC results obtained 
after storage were compared with spiked concentration values by determining the 
percentage ratios of experimental values divided by spiked values. 
The stabilities of stock and working solutions for both analyte and internal standard were 
also evaluated. Stock solutions of analyte and IS were stored at -20 0C for 9 months. From 
both stored and fresh stock solutions, two QC standards (1.25 and 80 ng/mL) were prepared 
for the analyte, to which 7.5 ng/mL IS (JCC76) was added, and the experimentally 
determined concentrations of BMCL26 and JCC76 were compared (n=3 for each). 
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3.3. Results and discussion 
3.3.1. Optimization of mass spectrometric conditions for quantitation 
The negative ionization mode was selected for both BMCL26 and JCC76 (IS) detection in 
this study because the analyte produced a much stronger signal for negative ionization 
compared to positive ionization. It was found that analyte and IS solutions prepared in 
methanol-water (9:1, v/v) yielded stronger signals compared to solutions prepared in 
acetonitrile-water (9:1, v/v). Adding ammonium acetate to the methanol–water solution 
substantially increased BMCL26 signals. Therefore, a gradient flow of methanol-water-
ammonium acetate was chosen for the HPLC mobile phase. Figure 3.2 showed the parent 
ion spectra for both BMCL26 and IS. The highest fragment-ion signals were obtained by 
fine-tuning the collision energy, spray voltage, and ion source temperature. Based on our 
ionization and fragmentation optimization results, we chose MRM transitions of m/z 573.3 
→ 493.2 for BMCL26 and 443.2 → 79.1 for IS for quantification, as these product ions 
yielded strong and stable signals.  
 
3.3.2. Optimization of HPLC conditions 
The gradient flow of the mobile phase, which was used with different flow rates, was as 
follows: A: 50 μM ammonium acetate in 2% methanol and mobile phase; B: 50 μM 
ammonium acetate in 90% methanol (see Table 3.1). Because the C-18 column had a carry-
over problem with BMCL26, a C-8 column was used instead. The C-8 column effectively 
resolved the carryover problem and also yielded a better peak shape. Thus, BMCL26 and 
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IS were separated using a C-8 column with a flow rate of 0.25 ml/min for 3.5 min, after 
which the flow rate was increased to 0.6 ml/min for column clean up and re-equilibration. 
Retention times were observed at 2.48 min for BMCL26 and 3.12 min for IS (Fig. 3.3B). 
The total run time was 8 min.  
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Figure 3.3, (A) MRM chromatograms of blank rat plasma in both IS and analyte 
windows (B) IS JCC76 (10 ng/ml, 3.12 min) and BMCL26 at LLOQ level (0.5 ng/ml 
2.48 min). 
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3.3.3. Linearity, sensitivity, selectivity, and LLOQ 
Using the concentrations of BMCL26 in the working solutions, plasma calibration curves 
were constructed over a concentration range of 0.5 – 100 ng/mL. Linearity results showed 
a quadratic fit for BMCL26 using an eight-point calibration curve (0.5, 1, 2.5, 5, 12.5, 25, 
50, and 100 ng/mL) with JCC76 (7.5 ng/mL) as the internal standard in the plasma samples. 
Excellent linearity was obtained with a correlation coefficient (r2) of 0.9993. The linear 
regression equation was y= 0.073x-0.0085.  This method exhibited high selectivity and 
displayed no interfering peaks in six different blank plasma samples from different sources. 
Using the calibration curve, the LLOQ of the method was determined to be 0.5 ng/mL. The 
accuracy and precision were determined for each lot of plasma at the LLOQ. The data were 
summarized in Table 3.2. 
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Table 3.2, Accuracy and precision of BMCL26 calibration standards in rat plasma (n=5, pooled plasma samples) 
 
 
 
 
 
 
 
Nominal Concentration 
[ng/mL] 
Determined Concentration 
[ng/mL] 
Accuracy 
[%RE] 
Precision 
[%CV] 
0.5 0.47±0.03 -7.46 5.59 
1 0.99±0.02 -0.22 2.09 
2.5 2.54±0.05 1.40 2.01 
5 5.14±0.27 2.80 5.24 
12.5 12.75±0.31 2.00 2.41 
25 25.27±0.73 1.08 2.90 
50 51.03±0.97 2.06 1.90 
100 98.26±0.99 -1.74 1.01 
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3.3.4. Accuracy and precision 
Intra- and inter-assay accuracies (%RE) and precisions (%CV) were evaluated by 
analyzing five replicates of low, medium, and high QC standards. As summarized in Table 
3.3, the assay’s Intra- and inter-day relative errors were 0.62 and 11.36%, respectively, and 
the assay’s Intra- and inter-day precisions were 0.84-3.47%, respectively. These values 
were within acceptable limits according to FDA guidelines. 
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   Table 3.3, Inter and intra-assay accuracy and precision of BMCL26 in rat plasma 
 
 
Intra- assay  Inter- assay 
Normal 
[ng/ml] 
Determined 
[ng/ml] 
Accuracy 
[%RE] 
SD 
Precision 
[%CV] 
 
Determined 
[ng/ml] 
Accuracy 
[%RE] 
SD 
Precision 
[%CV] 
1.25 
10 
80 
1.20 
10.20 
80.70 
11.36 
2.00 
0.87 
0.02 
0.16 
0.68 
1.72 
1.64 
0.84 
 
1.36 
10.20 
80.50 
9.12 
2.00 
0.62 
0.04 
0.35 
2.80 
3.38 
3.43 
3.47 
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3.3.5. Extraction recovery and matrix effect 
It was found that protein precipitation was a good way to extract BMCL26 from plasma. 
Initially, we used 80% acetonitrile to precipitate plasma proteins, but a strong matrix effect 
was observed. Consequently, we utilized pure acetonitrile to precipitate proteins with 0.1% 
formic acid (for deproteinization). The latter precipitation conditions eliminated the matrix 
effect and achieved symmetrical chromatographic peak shapes. The absolute and relative 
extraction recoveries were in the range of 90.16-105.00%. The results were summarized in 
Table 3.5. As shown in Table 3.4, the absolute and relative matrix effects of BMCL26 from 
six different rat plasma samples at three QC concentrations low (1.25 ng/mL), medium (10 
ng/mL), and high (80 ng/mL) ranged from 101.30 – 110.10%. 
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Table 3.4, Absolute and relative matrix effect of BMCL26 in rat plasma 
 
 
 
 
 
 
 
 
 
Concentration of QC 
samples[ng/ml] 
Absolute  Relative 
Mean matrix 
effect 
%CV  Mean matrix effect %CV 
1.25 
10 
80 
105.00 ± 1.07 
107.00 ± 6.06 
105.00 ± 3.86 
1.02 
5.66 
3.68 
 
108.00 ± 5.15 
110.10 ± 8.99 
101.30 ± 4.78 
4.77 
8.17 
4.72 
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Table 3.5, Absolute and relative extraction recovery of BMCL26 in rat plasma 
 
 
Concentration of QC 
samples[ng/ml] 
Absolute  Relative 
Mean extraction 
recovery 
%CV  
Mean extraction 
recovery 
%CV 
1.25 
10 
80 
104.00 ± 4.89 
105.00 ± 4.99 
96.30 ± 3.00 
4.70 
4.75 
3.12 
 
98.10 ± 9.73 
95.96 ± 3.61 
90.16 ± 2.87 
9.92 
3.76 
3.18 
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3.3.6. Stability 
The stability of BMCL26 was determined by comparing the mean peak area ratios of 
BMCL26 to IS in low (1.25 ng/mL) and high (80 ng/mL) QC samples to those of freshly 
prepared QC solutions (containing the same concentrations), expressed in terms of 
recovery. As shown in Table 3.6, the receives of LQC and HQC samples were 103.46 – 
103.20%, 98.13 – 105.20%, and 101.86 – 107.54% for bench top conditions, after 3 freeze-
thaw cycles and post extraction at room temperature for 10 hours, respectively. The 
stabilities of working solutions of BMCL26 and internal standard (JCC76), stored at 4 ◦C 
for at least 6 months, were determined to be 99.60 – 105.00% and 115.60% for the two QC 
standards tested (1.25 and 80 ng/mL), to which 7.5 ng/mL IS was added (using the stored 
stock solution). These stability results showed no significant deviations in BMCL26 
quantification under the experimental conditions used. 
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Table 3.6, Stability of BMCL26 in plasma samples 
 
 
Storage conditions 
Concentration 
[ng/ml] 
Recovery 
% 
Bench top[8hr] 
At room temp 
1.25 103.46 
80.00 103.20 
Freeze-thaw [3 cycles] 
1.25 98.13 
80.00 105.20 
Post extraction 
[10hrs] at room temp 
1.25 101.86 
80.00 107.54 
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3.4. Conclusion  
This innovative method offers several advantages for assaying BMCL26 in rat plasma 
including simplicity, cost effectiveness, accuracy, and precision were below 11% and 
3%, with high sensitivity and selectivity. To our knowledge, this is the first time this 
method was used. This assay employed a simple protein precipitation procedure for 
plasma sample preparation. The LLOQ was as low as 0.5 ng/mL. The results from the 
validation study illustrated that this method can be used to determine the pharmacological 
and toxicological profiles of BMCL26 in rats in the future.   
 
3.5. Acknowledgements 
The authors acknowledge the following sources of support for this work: NIH grant 
R15AI 103889 (B. Su) and the National Science Foundation Major Research 
Instrumentation Grant (CHE-0923398).  
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
3.6. References  
 
[1] Barrett, M. P. 2006. The rise and fall of sleeping sickness. Lancet. 367:1377-
1378. doi: 10.1016/S0140-6736[06]68591-7.  
[2]  Barrett, M. P., R. J. Burchmore, A. Stich, J. O. Lazzari, A. C. Frasch, J. J. 
Cazzulo, and S. Krishna. 2003. The trypanosomiases. Lancet. 362:1469-1480. 
doi: 10.1016/S0140-6736[03]14694-6.  
[3]  Brun, R., J. Blum, F. Chappuis, and C. Burri. 2010. Human African 
trypanosomiasis. Lancet. 375:148-159. doi: 10.1016/S0140-6736[09]60829-1.  
[4]  Frankish, H. 2003. The initiative launched to develop drugs for neglected 
diseases. Lancet. 362:135.  
[5]  Steverding, D., and K. M. Tyler. 2005. Novel antitrypanosomal agents. Expert 
Opin. Investig. Drugs. 14:939-955. doi: 10.1517/13543784.14.8.939. 
[6]  Issa, V. S., and E. A. Bocchi. 2010. Antitrypanosomal agents: treatment or 
threat? Lancet. 376:768; author reply 768-9. doi: 10.1016/S0140-
6736[10]61372-4.  
[7] Heald, R., and E. Nogales. 2002. Microtubule dynamics. J. Cell. Sci. 115:3-4.  
[8] Kuppens, I. E. 2006. The current state of the art of new tubulin inhibitors in the 
clinic. Curr. Clin. Pharmacol. 1:57-70.  
[9] Werbovetz, K. A. 2002. Tubulin as an antiprotozoal drug target. Mini Rev. Med. 
Chem. 2:519-529.  
[10] Okuno, M., D. J. Asai, K. Ogawa, and C. J. Brokaw. 1981. Effects of antibodies 
against dynein and tubulin on the stiffness of flagellar axonemes. J. Cell Biol. 
91:689-694.  
90 
 
[11] Werbovetz, K. A., D. L. Sackett, D. Delfin, G. Bhattacharya, M. Salem, T. 
Obrzut, D. Rattendi, and C. Bacchi. 2003. The selective antimicrotubule activity 
of N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide [GB-II-5] against 
kinetoplastid parasites. Mol. Pharmacol. 64:1325-1333. doi: 
10.1124/mol.64.6.1325.  
 
[12] Benbow, J. W., E. L. Bernberg, A. Korda, and J. R. Mead. 1998. Synthesis and 
evaluation of dinitroanilines for the treatment of cryptosporidiosis. Antimicrob. 
Agents Chemother. 42:339-343.  
[13] Morejohn, L. C., and D. E. Fosket. 1984. Inhibition of Plant Microtubule 
Polymerization in vitro by the Phosphoric Amide Herbicide Amiprophos-
Methyl. Science. 224:874-876. doi: 10.1126/science.224.4651.874.  
[14] Murthy, J. V., H. H. Kim, V. R. Hanesworth, J. D. Hugdahl, and L. C. 
Morejohn. 1994. Competitive Inhibition of High-Affinity Oryzalin Binding to 
Plant Tubulin by the Phosphoric Amide Herbicide Amiprophos-Methyl. Plant 
Physiol. 105:309-320.  
[15] Dawson, P. J., W. E. Gutteridge, and K. Gull. 1984. A comparison of the 
interaction of anthelmintic benzimidazoles with tubulin isolated from 
mammalian tissue and the parasitic nematode Ascaridia galli. Biochem. 
Pharmacol. 33:1069-1074.  
[16] Wu, D., T. G. George, E. Hurh, K. A. Werbovetz, and J. T. Dalton. 2006. Pre-
systemic metabolism prevents in the vivo antikinetoplastid activity of N1,N4-
91 
 
substituted 3,5-dinitro sulfanilamide, GB-II-150. Life Sci. 79:1081-1093. doi: 
10.1016/j.lfs.2006.03.028.  
[17] Yi, X., B. Zhong, K. M. Smith, W. J. Geldenhuys, Y. Feng, J. J. Pink, A. 
Dowlati, Y. Xu, A. Zhou, and B. Su. 2012. Identification of a class of novel 
tubulin inhibitors. J. Med. Chem. 55:3425-3435. doi: 10.1021/jm300100d.  
[18] Zhong, B., X. Cai, S. Chennamaneni, X. Yi, L. Liu, J. J. Pink, A. Dowlati, Y. 
Xu, A. Zhou, and B. Su. 2012. From COX-2 inhibitor nimesulide to the potent 
anti-cancer agent: Synthesis, in vitro, in vivo and pharmacokinetic evaluation. 
Eur. J. Med. Chem. 47:432-444. doi: 10.1016/j.ejmech.2011.11.012.  
[19] Lama, R., R. Sandhu, B. Zhong, B. Li, and B. Su. 2012. Identification of 
selective tubulin inhibitors as potential anti-trypanosomal agents. Bioorg. Med. 
Chem. Lett. 22:5508-5516. doi: 10.1016/j.bmcl.2012.07.023 [doi].  
 
[20] Suleyman H, Halici Z, Cadirci E, Hacimuftuoglu A, Bilen H. 2008. Indirect role 
of beta 2 –adrenergic receptors in the mechanism of anti-inflammatory action 
of NSAIDS. J Physiol Pharmacol. Dec; 59[4]: 661–72. 
[21] FDA Bio analytical method guidelines for industry, U.S. department of health 
and human services food and drug administration, 2001 
www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf. 
[22] Liu Y, Ma B, Zhang Q, Ying H, Li J, Xu Q, Wu D, Wang Y. 2013. Development 
and validation of a sensitive liquid chromatography/tandem mass spectrometry 
method for the determination of raddeanin A in rat plasma and its application 
92 
 
to a pharmacokinetic study.Journal of Chromatography B, Analytical 
Technologies in the Biomedical and Life Sciences 2013; 912: 16-23. 
[23] Ito H, Yamaguchi H, Fujikawa A, Shiida N, Tanaka N, Ogura J, Kobayashi M, 
Yamada T, Mano N, Iseki K. 2013 Quantification of intact carboplatin in human 
plasma ultrafiltrate using hydrophilic interaction liquid chromatography-
tandem mass spectrometry and its application to a pharmacokinetic study. 
Journal of Chromatography B, Analytical Technologies in the Biomedical and 
Life Sciences 2013; 917- 918: 18-23. 
[24] Voggu RR, Alagandula R, Zhou X, Su B, Zhong B, Guo B. 2014. A rapid LC-
MS/MS method for quantification of CSUOH0901, a novel antitumor agent, in 
rat plasma. Biomed. Chromatogr. 2014. 
 
 
 
 
 
 
 
 
93 
 
 
 
 
 
 
 
 
Part - II 
 
 
 
 
 
 
 
94 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
REVIEW OF HCC AND DNA METHYLATION 
 
4.1. Introduction 
DNA Methylation is the covalent chemical modification resulting in addition of methyl 
group at 5th carbon position of the cytosine ring. DNA methylation is a naturally 
occurring event in both prokaryotes and eukaryotes. In prokaryotes, they majorly play a 
role of protection of the host DNA from restriction endonucleases produced to destroy 
foreign DNA [1]. However, they have a complicated role in eukaryotes like gene 
imprinting, X chromosome Inactivation, embryonic development and cell cycle 
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regulation. When we consider the classic view of DNA methylation, it varies according 
to the developmental stages namely pre and post developmental processes. The former 
pattern associates the methylation processes into active or passive methylation whereas 
the latter involves its maintenance based on DNMT’s [2]. DNA methylation errors are 
potentially reversible and as a result aid in Pharmacological changes. 
 
4.1.1. DNA methylation and carcinogenesis 
Aberrant changes in the DNA methylation promote disease state. Aberrant DNA 
methylation is found in two distinct forms namely hyper methylation and DNA 
hypomethylation. Hyper methylation is usually associated with the gene inactivation 
involving CpG islands and hypo methylation involving repeated DNA sequences of 
nuclear elements [3]. These two processes are independent processes [4]. 
 
4.1.2. Hypermethylation in cancer  
It is one of the most studied epigenetic changes in cancer. DNA hyper methylation 
typically occurs in the CpG islands. The promoter site and transcription site are included 
within the CpG islands and when hyper methylation occurs at these islands, the 
expression of gene is totally repressed leading to gene inactivation [5]. 
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4.1.2.1. CpG islands 
DNA is made up of four bases namely Adenine, Guanine, Cytosine and Thymine. Among 
these four bases, the numbers of dinucleotide combinations possible are 16 [6]. Out of 
which, the cytosine methylation occurs in 5’CG 3’ dinucleotide combination. Based 
on the percentage of these combinations, the frequency of these dinucleotides should be 
10% but only occur around 5% [7]. Methylation isn’t uniform through the human 
genome, containing both methylated and unmethylated segments. Unlike the rest of the 
genome, CpG islands are interspaced on an average of 100kb and ranging up to 5kb are 
smaller regions of unmethylated DNA which are GC rich, Guanine Adenine content 
above 0.5 and having distinctive properties without any suppression of the occurrence of 
dinucleotide CpG. It is known that human genome contains around 29000 CpG islands 
and is associated with about 60% of mammalian genes, mostly in promoter and first exon 
region of genes. In normal, healthy tissues CpG islands are unmethylated but these are 
methylated to various extents in cancer [8]. There are different protective mechanisms 
that prevent the hyper methylation at these CpG islands like demethylation, changes 
in chromatin structure, active transcription and timing of replication [6]. As the figure 
1.1 indicates, DNA methylation is a reversible reaction and the active chromatin recruit’s 
DNA demethylases, the enzymes responsible for DNA demethylation and inactive 
chromatin recruits DNMT’s. Therefore, if the chromatin structure is maintained DNA 
methylation is maintained. Hyper methylation is region specific and the local changes 
around this specific region of genes inhibit them from interacting with the demethylases, 
protecting them from demethylation. 
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Figure 4.1, The methylation state of a gene is equilibrium of methylation and 
demethylation reaction [9]. 
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4.1.2.2. Global hypo methylation in cancer 
Global DNA hypo methylation was the first identified epigenetic event in cancer. Hypo 
methylation is the loss of methylation and this loss is quite predominantly seen as they 
are quantitative in nature and affect a variety of repetitive sequences which are dispersed 
throughout the genome. Usually, the pericentric regions of chromosome 1-16 are hypo 
methylated, with most cases occurring in regions with sparsely distributed CG sequences. 
Hypo methylation plays a role in cancer by various mechanisms like instability of the 
chromosome [10], activation of the long interspread nuclear elements called 
retrotransposons in the genome [11]. Hypo methylation of these transposons, which are 
usually latent, may lead to oncogenesis by transcriptional activation and sometimes may 
express themselves on the adjacent genes [12]. 
 
4.1.3. DNA methylation machinery 
Based on the methylation patterns of CpG dinucleotides on both strands, DNA 
methylation can be either Denovo Methylation or Maintenance Methylation. Denovo 
Methylation occurs, when the CpG dinucleotides on both the strands are unmethylated 
and has an important role in cell growth, differentiation and tumor genesis.  Maintenance 
methylation occurs when CpG dinucleotides on only one strand are methylated [9]. It 
mainly copies the DNA methylation patterns but does not introduce any different 
methylation patterns. As the figure 1.2 suggests, DNA methylation machinery can be 
classified into two ways namely, transcriptional repressor machinery to the 
corresponding promoter CpG island which contribute to tumorigenesis by silencing of 
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TSG’s and the Transcriptional Activation machinery for the active expression of the 
oncogene. 
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Figure 4.2, Epigenetic provides a new generation of oncogene and tumor- 
suppressor genes 
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Transcriptional Repressor Machinery include DNA methyl transferases, Methyl CpG 
Binding proteins, histone methyltransferases for lysine 9 of histone H3 (HMT K9 H3), 
histone deacetylases and polycomb. Transcriptional Activator machinery includes 
HAT’s, HMT’s and others. Of these, epigenetic machinery DNMT’s, MBD’s and HAT’s 
play an important role in DNA methylation. 
 
4.1.4.  DNA methyltransferases [DNMTs] 
DNA methyl transferases are the enzymes that catalyze the transfer of the methyl group 
from the methyl donor S-adenosyl methionine onto the DNA and release S-adenosyl 
homocysteine [13]. DNMTs are the critical proteins involved in establishing proper 
control of epigenetic information. In mammals, four different types of DNMTs are seen 
DNMT1, DNMT2, DNMT3a and DNMT3b. The balance of DNMT’s is very important 
to prevent cell transformation. The DNMT’s in conjugation with accessory proteins like 
DNMT3L are mainly responsible for DNA methylation at various stages like 
embryogenesis and development of somatic tissue [14]. 
DNMT 1 is the most abundantly found among DNA methyl transferases. It is useful in 
maintaining the post replicative DNA methylation patterns. It is useful for maintaining 
the methylation pattern during cell division. The DNA Methylation patterns are passed 
on from the parental strand to daughter cells and DNMT1 maintains this maintenance 
methylation [15]. It also plays an important part in Denovo methylation [16]. They 
maintain gene silencing in cancer cells, by cooperative interactions between DNMTS 
especially DNMT1 and DNMT3b. DNMT 2, is not involved much in DNA methylation. 
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However, it can contribute to cancer through different pathways related to RNA. 
DNMT3b is mainly involved in Denovo methylation. It is also a part of several 
complexes. It inhibits gene expression by forming a transcription repressive complex. 
DNMT3B leads to demethylation when it is deleted and with DNMT1 and maintain the 
global methylation [17]. 
 
4.1.5.  Methyl CpG binding domain proteins 
MBD proteins are considered interpreters of DNA methylation. They are important 
between DNA methylation and genes involved in histone modifications. All of them bind 
to the CpG sites with the exception of MBD3 [18]. Twelve different types of Methyl CpG 
proteins have been identified of which MBD1, MBD2, MBD3, MBD4 and MeCP2 
are the most important members [17]. They play a role in the pathophysiology by a 
number of mechanisms. They associate with the CpG island promoters of the Tumor 
suppressor genes and lead to transcriptional silencing. MBD4 is different when compared 
to other MBDs as it is a thymine glycolase and it helps in DNA repair protein, as the 
Glycolase domain removes thymidine from T: G mismatches [19]. 
 
4.1.6.   Histone modification enzymes 
Histones are used to store the epigenetic information through modifications of the amino 
terminal protruding tails. These modifications generally include acetylation, 
phosphorylation, and methylation. Histone Modification Enzymes involved are histone 
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acetyl transferases (HATs), Histone methyltransferases (HMTs) and histone deacetylases 
(HDACs). HATs are involved in the Acetylation of histone lysine’s and HMTs aid in the 
deacetylation. 
 
4.2. Hepatocellular carcinoma  
Primary Liver cancer can be distinguished into three main types namely Hepatocellular 
Carcinoma which occurs from Hepatocytes, Duct cell Carcinoma and 
cholangiohepatoma which occurs from intrahepatic bile ducts. Clinically there is not 
much difference between them since they spread throughout the liver [20]. Primary Liver 
Cancer is unique when compared to all the malignancies because of its worldwide 
distribution, association with cirrhosis, spontaneity of the tumor and inherent difficulties 
[21]. Primary Liver Cancer is the fifth most common cancer in the world and second 
rated cancer with most deaths [22]. Hepatocytes, the parenchymatous cells which are 
chiefly responsible for its functioning and their uncontrolled division leads to primary 
liver cancer in most cases. Hepatocellular Carcinoma is the predominant type of liver 
cancer and also called as hepatoma based on its occurrence and it accounts for about 85-
90% primary liver cancers [23]. HCC is the fifth most common cancer in men and eighth 
most common in women. Hepatocellular Carcinoma is usually asymptomatic, with 
Cirrhosis being the major condition present in about 80-90% of them and by the time 
of diagnosis it is usually advanced leaving with a 5-year survival rate. Hepatocellular 
Carcinoma have different growth patterns with some starting as single tumor and grows 
large before spreading and others appear as small spots in various areas. It is very 
important to diagnosis HCC early to improve the survival rate. 
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4.2.1. Epidemiology of hepatocellular carcinoma 
Several epidemiological factors like age, sex, ethnicity, distribution of risk factors 
influence HCC. Geographically speaking, greater number of the cases of HCC is found 
either in sub-Saharan or Asian populations. In United States, the rates of incidence 
increased at a two-fold rate between 1985 and 2002. When you compare ethnicity among 
different regions, Asians are twice susceptible to HCC than Americans. This might 
depend on the differences in attainment of the risk factors of HCC. The age is an 
interdependent epidemiological factor based on various factors like sex, age of infection 
and so on. Hepatitis B Virus usually infects at younger age when compared to HCV. 
Throughout the world, age of incidence of HCC in men is approximately 5 years lower 
when compared to that of women. Sex of an individual highly influences the incidence 
rate because, throughout the ratio of incidence between male and female is either 
two fold or four fold with male dominating. This again might be due to various factors 
like exposure to viral factors, alcoholism and smoking with largest difference in ratios 
seen in European populations. Studies conducted state that men have higher BMI 
and higher level of androgenic hormones might be a reason for higher incidence of HCC. 
HBV and HCV are the two most dominant risk factors in HCC. However, their 
distribution varies from place to place. Globally, HBV risk factor is more dominant. 
In places like Japan HCV show greater dominance than HBV. 
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4.2.2. Risk Factor for hepatocellular carcinoma 
The risk factors of HCC can broadly be categorized into pathological factors, 
physiological factors, exposure to environmental toxins and dietary factors [23]. The 
physiological factors like geography, age and sex are mostly patterns of the pathological 
factors mostly HCV, HBV and alcohol liver disease [24]. The physiological factors for 
HCC incidence increase with age and males have greater chance of Incidence than 
females. The pathological factors can be categorized into Hepatitis B virus and Hepatitis 
C virus. Liver Cirrhosis can be considered to be the main precursor because about 70% 
have HBV related Cirrhosis when compared to the 20% HCV related Cirrhosis [25]. 
Various studies show that incidence of HCC in patients with chronic Hepatitis or 
Cirrhosis is greater when compared to the patients with normal transaminases [26]. HCV 
does not play a direct role in HCC. However, it leads to development of Cancer through 
Cirrhosis. Exposure to environmental Toxins like Aflatoxin, which is a product of 
Aspergillus fungus, on the legume crops is less developing countries and on dietary 
intake of them leads to development of HCC [27, 28]. Alcohol does not have any 
particular mutagenic properties. Effect of Consumption of Alcohol is usually dose 
dependent and leading to HCC through Cirrhosis. It was proved in a Cirrhosis study that 
chances of HCC are 13 times greater in people consuming alcohol when compared to 
people who stay away from it [29]. Smoking is also an important factor in HCC, with 
studies showing a contribution of about 50% in HCC [30]. Few of the rarer factors which 
influence HCC are hemochromatosis which is a genetic factor and few metabolic diseases 
like Diabetes type-II, glycogen storage disease type 1 and alpha-1 antitrypsin deficiency 
[31]. 
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4.2.3.  Molecular mechanisms of hepato- carcinogenesis 
The pathophysiology of HCC is mainly based upon cirrhosis. Different molecular 
mechanisms inhibit the regenerative capacity of the liver at cirrhotic stage and these 
mechanisms tend to increase the rate of carcinogenesis at cirrhotic stage. They can be 
classified into cell intrinsic alterations and cell extrinsic alterations [23]. Cell intrinsic 
alterations involved are the shortening of the length of telomere which restricts the 
proliferation of hepatocytes [32, 33], thereby leading to induction of chromosomal fusion 
by activating DNA repair pathways [34, 35]. Cell extrinsic alterations involved mainly 
are the decrease in the proliferation of the primary liver cells and changes in the micro 
and macro environment, thereby promoting risk of cancer Figure 4.3. 
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Figure: 4.3, Molecular mechanisms of hepatocellular carcinoma at the cirrhotic 
stage [23]
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4.2.4. Staging and diagnosis of hepatocellular carcinoma 
The method developed by Okuda et al is the most commonly used staging system 
presently. This system evaluates the albumin levels, size of the tumors and concentration 
of bilirubin of patients. However, it is ineffective at early stages of the disease. Several 
prognostic staging systems are currently in clinical use like Barcelona Clinic Liver 
Cancer, Tumor node metastasis which although advanced does not consider underlying 
Cirrhosis. Although they all differ on the way of evaluation, they are useful in better 
understanding of diagnosis. 
HCC Tumor is categorized by AJCC, into various stages based on the clinical status 
of the patient, the size of the tumor, the number of lesions. Stage I and II with the tumor 
showing some Invasiveness in the blood vessels and forming single to multiple tumors. 
In stage III a, multiple tumors are formed which tend to increase in size and these tumors 
extend to the hepatic vein by stage III b and reach the visceral peritoneum by Stage III 
c. In stage IV a and IV b leads to initially regional to distant metastasis [36, 37]. 
Diagnosis of HCC involves differential Diagnosis of well differentiated HCCs from 
lesions and poorly differentiated HCCs from malignancies similar to HCC outside liver. 
Usually well differentiated HCC’s from dysplastic nodules and poorly differentiated 
HCC’s from metastatic tumors, chlorangiosarcoma [38]. Diagnosis is mostly possible 
only when symptoms like weight loss or sometimes much more severe like liver failure 
are seen and usually suggesting presence of tumored liver [39]. Some of the common 
methods of diagnosis include imaging like CT scan, MRI. The noninvasive nature, fewer 
costs make imaging more preferable though they are late in detecting only until large 
tumors are formed [40]. The confirmation of the pathology of HCC play a role in 
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diagnosis and biopsy is a method of doing it. However, it also chances of spreading the 
disease. 
 
4.2.5. Current treatment options 
Surgical resection is the preferred method for very early HCC. It is usually indicated in 
patients without cirrhosis and portal hypertension. Patients with preserved liver function 
are resected. The only problem it faces is recurrence. However, in combination with 
adjuvant therapy it can be controlled. Liver transplantation is another method for 
treatment of early HCC and is suitable for patients without proper functioning of liver 
and any extra hepatic spread or vascular invasion and nodules of size less than 5cm. 
However, the demand of livers and waiting time is a problem. If the waiting time 
is greater than 12 months 25% more chances of tumor being spread. Ablation is a method 
with similar recurrence chances and survival rates when compared to Surgical Resection. 
It is effective when nodules are below 2cm [41]. Percutaneous ethanol injection has been 
the most successful technique of ablation with little adverse effects. It is time taking and 
ineffective in tumors larger than 3cm. RFA solves most of these issues of the PEI with 
greater side effects [39]. Some other common ablation techniques are microwave and 
cryoablation. For patients, with Intermediate HCC and multi nodular tumors without any 
invasion and extra hepatic spread, Transcatheter Arterial Chemo embolization and Trans-
arterial embolization with a radioactive isotope Y90 was used. For patients with 
Advanced HCC, systemic therapy with Sorafenib, a multi kinase inhibitor is mostly used 
and few others like Sunitinib, brivonib and being investigated [42, 43].
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4.2.6. Current trends in research of biomarkers for hepatocellular carcinoma 
HCC is usually asymptomatic and biomarkers therefore act as measurement tools for 
diagnosis of the disease, its progression and help to target a proper therapeutic treatment. 
Different types of Biomarkers are presently used worldwide. Alpha–Feto protein is the 
most commonly used biomarker presently and can be called as a gold standard, it is pretty 
much useful in patients with known risk factors as its increase is directly in 
correspondence with the development of HCC [44] [45]. However, it does not correlate 
much to the prognostic factors of HCC. 
Different types of immuno histochemistry markers are useful as diagnostic markers as 
they use immunochemical staining to distinguishing well differentiated HCC. Some of 
them are HSP70, Glypican 3. These usually appear and reappear during tumor genesis 
and usually used in combinations [46]. Some of the IHC markers used in prognosis are 
Ki67, Survivin and E-Cadherin. Enzymes and Iso-enzymes used as biomarkers like Des- 
Gamma-Carboxy Prothrombin which when used with AFP increases the sensitivity, 
gamma glutamyl tranferase also is used in combinations with AFP and DCP increases 
the sensitivity [47].  Several growth factors like fibroblast growth factor, epidermal 
growth factor receptor family and hepatocyte Growth Factor are used. Hepatocyte 
Growth factor plays an active role as biomarker in prognosis and recurrence. It plays 
a role in HCC through the pancrine system involving the receptor c-met. Circulating 
Nucleic acids mainly mRNA, like GGT mRNA, IGF-2 mRNA are analyzed in various 
pathological and physiological conditions. Micro RNAs provide new insights into HCC 
carcinogenesis and therefore used in prognosis and diagnosis of the disease. Depending 
upon the etiology of the HCC and the molecular abnormalities make it pretty difficult to 
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find a biomarker with good specificity and sensitivity. These are the currently used 
markers based on the different molecular pathways of HCC and these show great amount 
of significance and on further research can be used to improve the prognostic values and 
assist in determining the proper mode of therapy. 
 
4.3. DNA methylation analysis techniques 
DNA methylation analysis techniques can be categorized based on chemical 
modification of molecules, the precipitation of methylated DNA by proteins which 
interact with the methylated cytosines [48]. It is important to choose a protocol on the 
basis of several factors like sensitivity, cost, specificity and the desired results. In the 
precipitation techniques, complexes are formed between the proteins and the methylated 
DNA. These proteins bind and enrich the methylated DNA. Several protocols use 
different proteins, as in MIRA protocol, a complex of MBDs with glutathione –S-
transferase isolates the methylated DNA [49]. MBD2 and MeCP2 methyl binding 
domain of MBD2 are the most commonly used in isolating methylated DNA [50]. 
MBDs are not specific and are affected by the methylation density of DNA [51]. Lack 
of Specificity and sensitivity limits the precipitation techniques usage. 
DNA methylation Analysis techniques using methylation sensitive restriction enzymes 
which are sensitive to the cytosine methylation in CpG can be used [52]. This method 
involves the division of DNA into two samples and then digests one with enzyme 
sensitive to the DNA and one without sensitive to DNA methylation and later the missing 
cuts of enzymes and methylation are compared [48]. However, the incomplete digestion, 
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buffer conditions, over dependence on the sequence of Restriction site and the 
distribution limits its sensitivity. Microarrays techniques are generally used in 
combination with few analysis techniques. High resolution arrays like oligonucleotide 
arrays have been used in analysis [53]. Some of the arrays used are SNP’s [54]. They 
cannot quantify the methylation level accurately and therefore acts as a drawback. 
Methylation Bead chip technology is the currently used microarray technique and it can 
effectively overcome the drawbacks [55]. The techniques which focus on the alterations 
of DNA depend mainly on the conversion of the methylated DNA by the treatment with 
sodium bisulfite. The figure 4.4, gives a small description of methods of the DNA 
Methylation Analysis techniques presently used. 
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Figure 4.4, DNA methylation analysis techniques 
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4.3.1. Methylation-specific PCR [MSP] 
MSP was one of the early changes which involved Bisulfite Conversion.  It was 
introduced by Herman and colleagues [56]. It is a standard PCR reaction used to analyze 
the methylation status of CpG islands. In this reaction, distinct methylation primer 
sets for the sequence of interest are used like, the unmethylated primers specific for the 
unmethylated DNA whereas the methylated primer specific for methylated DNA. The 
unmethylated cytosine’s are converted to thymine’s and methylated cytosine’s are 
unconverted and therefore the primers designed should include CpGs of interest. When 
compared to other DNA methylation techniques MSP exhibits several advantages based 
on the simplicity of the procedure, time taken for and lack of need of any specific 
equipment. It is also less expensive and the presence of larger number of the CpG sites 
in the CpG islands. These factors aid the use of MSP in larger number of samples with a 
better sensitivity. It is also used in the prevention of unwanted non tumor cells in the 
sample, if a uniformly opposite pattern is observed by the tumor cells thereby increasing 
the detection [57].  However, it is difficult to obtain good capability as it is a very 
laborious process. It depends on various critical factors like Bisulfite Conversion, 
designing of the primer and PCR. 
 
4.3.2. Bisulfite conversion 
 
The existence of 5-methyl cytosine in the DNA is a very important area of study in the 
present genomic era. One of the most important Analytical method to determine the sites 
of the 5-Mc in the genome is the bisulfite modification of the genome [58]. To understand 
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the role of DNA methylation in various disease states it is very important to quantify and 
detect the 5-Mc and bisulfite modification is considered as a very efficient method and a 
gold standard in doing so [59]. 
 
4.3.3. Principle of bisulfite conversion 
It is based on the selective reactivity of sodium bisulfite with cytosine’s and methylated 
cytosine’s.   The   chemistry   of   cytosine   deamination   involves   three   steps   namely, 
Sulfonation which involves addition of bisulfite to the 5, 6 bond of the cytosine in 
the presence of acidic pH, hydrolytic deamination which is an irreversible conversion of 
cytosine bisulfite derivative to Uracil bisulfite derivative aided by some free radical 
scavengers to prevent any oxidization. This is followed by the alkali desulfonation of the 
Uracil bisulfite derivative to Uracil in the presence of an alkali to decrease the pH and 
aid in desulfonation [60]. Bisulfite treatment deaminates cytosine to Uracil and leave 5- 
methylcytosine unchanged. One of the major advantage of this method is the integrity of 
the DNA is maintained and thus enable various techniques for amplifying or analyzing 
DNA to be performed on the bisulfite modified DNA, thereby can startup with 
low Concentrations of DNA [48] Figure 4.5. 
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Figure 4.5, Bisulfite mediated conversion of cytosine to uracil [61]
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The efficiency of the bisulfite conversion is dependent on the following errors like [62], 
failed conversion when unmethylated cytosine do not undergo deamination and as a 
result it appears methylated and thus gives an increased estimation of methylation and 
often it can be corrected by increasing the time of bisulfite treatment or by increasing the 
number of denaturation steps [63], by doing so can also prevent the renaturation of 
sample DNA. Inappropriate conversion is another important problem which occurs when 
methylated cytosine undergo deamination yielding thymine and they like Uracil pair up 
with adenine during PCR and are misinterpreted as unmethylated leading to 
underestimation of the methylation density [64]. Depurination during the time of 
conversion is another notable problem by failing of enzymatic reactions when using 
negligible amounts of DNA [65]. Degradation of template DNA is a very common side 
effect seen and it affects the detection limit of method but how much of DNA is lost during 
the reaction is not known. Usually, at a temperature of 95-degree Celsius DNA degrades 
rapidly and thus higher temperatures are preferred only if sufficient amount of DNA is 
available and it is always advisable to keep the incubation time as low as possible since it 
is evident that the longer the incubation time greater the degradation [64]. However, DNA 
methylation Analysis on the basis of bisulfite modification are performed on a larger 
spectrum and many methods of amplification enable a bisulfite converted DNA 
concentration of 50ng sufficient and thus enabled the design of various techniques based 
on bisulfite conversion. 
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4.3.4. Primer design 
The primer design is a very important parameter and is essential in determining the 
methylation status of a gene promoter. Some of the important parameters to be taken care 
while designing a primer are, they should be at a length of 23-24 bp to achieve desired 
gene specific annealing [66]. Exact Annealing temperature of the primer has to be 
determined, because low stringency leads to mismatching and MSP depends on specific 
annealing to the DNA. Amplification of the unconverted CpG dinucleotide which is 
unmethylated may show greater methylation levels. Therefore, the primers should be 
designed to be specific to Bisulfite modified DNA and also contain few non CpG cytosines 
in the original template [48]. 
 
4.3.5. Applications of MSP 
 
Various methods of MSP have been developed to increase the sensitivity of detection of 
MSP for the methylated DNA. Nested MSP is on such method which is more sensitive 
and allows detection of very small quantities of DNA. However, problems like 
renaturation, incomplete bisulfite conversion and lack of accurate information about the 
single strand are seen [67, 68]. Quantitative MSP is useful to quantify the number of 
methylated alleles. It is mainly advantageous as it does not involve steps like gel 
electrophoresis, enabling it’s us as an important tool in fast screening [69]. 
It is very difficult to find out the exact timing of the methylation changes by MSP. To 
prevent these types of issues ISH have been used. It was used in combination with MSP 
and aid in the detection of methylated DNA on tissue slides [70].  It is used to examining 
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the progress of tumor, CpG island methylation and gene expression. HPLC is also used 
and various forms of HPLC like denaturing HPLC are used in combination with MSP 
and they detect methylation patterns based on the denaturation temperatures [66]. Ion 
Pair-Reverse phase HPLC was also used to distinguish between methylated and 
unmethylated with the help of deoxynucleotides [71]. Denaturing gradient gel 
electrophoresis is a method based on the thermal stability useful to detect the overall 
methylation differences and it is the first study to differentiate between methylated, hemi 
methylated and unmethylated sites [72, 73]. These are some of the methods which use 
MSP as a combination and try to increase the sensitivity of the MSP and aid in better 
detection between methylated and unmethylated DNA. 
 
4.4. Biomarkers 
A biomarker can be defined as, an indicator used to measure the normal biological 
function, pathogenicity and response to drug treatment [74]. A biomarker can either be 
secreted by the malignancy itself or as a physiological response to the presence of the 
cancer. A clinical end point usually determines the efficacy and the biomarkers are 
mainly used to form an intermediate endpoint and are thus used to monitor earlier stages 
of carcinogenesis [75]. Biomarkers are distinguished mainly into two types, Biomarkers 
which are used to determine the successful dosage levels required and those which are 
used to determine the progress of a disease [76]. Biomarkers in cancers have 
multidimensional role [77], they serve in screening studies and diagnosis. Biomarkers 
used in screening studies usually check the existence of any premalignant conditions or 
the exposure and in diagnostic role, they are mainly used to diagnosis the presence or 
120 
 
absence of cancer in a certain individual. They also constitute a role in the prevention 
trials of cancer and its treatment as they focus on various effects, like the side effects 
induced and they further focus on the toxicities rather than the desired result. The primary 
defect in Cancer is in the genomic DNA and alterations of DNA like translocation, 
mutations, aberrant DNA methylation play a major role in carcinogenesis and the 
biomarkers which can bring about these DNA alterations are used as potential tumor 
biomarkers. The use of DNA as a tumor marker has several advantages. When in 
comparison with proteins they can be amplified and therefore useful in the detection of 
minute quantities of the samples. High stability when compared to m-RNA and the 
proteins which aids its survival in adverse conditions for longer periods [78]. 
 
4.4.1. DNA methylation as a bio-marker 
The aberrant methylation of the promoter regions of genes is seen both in early as well as 
advanced cancers and when DNA with these aberrantly methylated genes is released into 
the blood serves as an indicator for the earlier detection of the cancer. This ability to 
detect cancer in its earlier phases makes DNA Methylation an important marker over 
other markers which cannot detect cancer in its earlier phases of tumorigenesis [79]. The 
involvement of DNA methylation in both onset as well as progression of different cancers 
enables it to serve a dual role both as a diagnostic and a prognostic marker of disease. The 
main advantage of DNA methylation over mutations which can arise at any point in the 
gene is its site specificity thus increasing its sensitivity of detection. 
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4.4.2. DNA methylation as a diagnostic marker 
Early diagnosis is very critical for the successful treatment of cancer. The traditional 
methods of diagnosis invasive as well as noninvasive like cytology, histopathology and 
immunohistochemistry are useful. The detection of cancer with minimal invasive 
procedure is always preferred. The changes in the marker should be specific so as to 
differentiate the level of malignancy and assess the premalignant conditions, thereby 
diagnosis the risk level of the progression of the malignancy. The sensitivity and the 
specificity of the DNA methylation marker depends on many factors in cancer diagnosis 
namely the type of body fluid used, type of cancer studied and techniques involved [6]. 
DNA methylation biomarkers can show few premalignant conditions which are not 
progressed to a level of detection detectable by other methods of detection by quantitative 
analysis of the levels before its progression to a fatal limit of malignancy. Some of the 
available diagnosis methods might show false results leading to further analysis and 
therefore costing time, money as well as psychological stress. This can be avoided by 
using DNA methylation markers in combination with other tests as a panel and therefore 
increasing the sensitivity and specificity of the screening procedures. 
 
4.4.3. DNA methylation as a prognostic and predictive bio-marker 
 
The genes which undergo methylation at any stage of the cancer progression act as 
potential prognostic markers whereas predictive biomarkers are the markers based upon 
the therapeutic results [80]. For determining the best therapeutic mode of treatment, 
patient’s response to the administered chemotherapeutic agent and survival, thereby 
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allowing monitoring of various changes accordingly, these markers are utilized. Usually 
prognosis is carried on in absence of the adjuvant therapy. 
Predictive markers are usually evaluated when measurable amount of disease is usually 
seen whereas prognostic effect is usually evaluated as a control without any systemic 
treatment. Prognostic factors are mainly utilized to differentiate patients based on the 
aggressive of the disease thereby treating them accordingly by avoiding the unnecessary 
side effects. However, it is still unclear in many reports whether the predictive or the 
prognostic impact has been observed. 
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CHAPTER V 
 
QUANTITATIVE METHYLATION ANALYSIS OF TUMOR ASSOCIATED 
GENES USING METHYLATION SPECIFIC PCR FOR THE DETECTION OF 
HEPATOCELLULAR CARCINOMA 
 
5.1. Introduction 
Hepatocellular carcinoma (HCC) represents a major international health problem as a result 
of its increasing incidence, with 700,000 new cases raised according to the records in 2012. 
The regions of the high incidence of HCC particularly in China, Thailand and Africa [1]. 
The survival rate of HCC is low due to its poor diagnosis and prognosis, high recurrence, 
and resistance to chemotherapy and radiotherapy [2]. Various epidemiological studies have 
shown that 70% of HCC cases in the United States and 75% of cases in developing 
countries are associated with HCV and HBV infection [3-5]. The major risk factors for 
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HCC are liver cirrhosis, hepatitis B and C virus, dietary aflatoxin exposure, obesity and 
excessive consumption of alcohol [6, 7].  However, the majority of HCC was detected in 
non-resectable advanced stages, which further prevents potential curative treatments. 
Recent reports demonstrate that epigenetic inactivation of gene expression by aberrant 
methylation on CpG islands may be a fundamental contributor to carcinogenesis and cancer 
progression [8 -10]. Based on direct inactivation of tumor suppressor genes, DNA 
hypermethylation can also block transcription factors and silence DNA repair genes, 
resulting in the loss of downstream gene functions and the accumulation of genetic lesions 
[11]. For HCCs, a growing number of genes undergo hypermethylation in liver tissues [12-
16]. Supporting the hypothesis that determination of methylation in specific genes may be 
useful for HCC diagnosis. Α-fetoprotein (AFP) testing, the only approved screening test, 
has been used to detect HCC for many years, but its sensitivity and specificity are marginal 
[17]. Hence, there is an urgency to establish a better set of DNA methylation markers for 
early diagnosis and prognosis of HCC. 
DNA methylation appears to be an emerging tumor biomarker and frequent promoter of 
methylation of various tumor suppressor genes [18-20]. Current testing assays utilize single 
DNA marker to detect HCC, but there is no single marker that is both sensitivity and 
specific enough to meet the HCC screening requirements. Recent studies demonstrated the 
advantages of multiple methylated genes in both tissue and plasma samples regarding 
diagnostic and prognostic information [21-23]. However, little was known about the value 
of DNA methylation analysis at multiple gene sites for the detection of HCC in various 
population. 
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The aim of this study was to identify a combination of methylated genes that was suitable 
for clearly well-differentiated between HCC and adjacent non-HCC, and to establish a 
user-friendly methylation-specific PCR (MSP) system to measure methylation status of 
these HCC gene markers. To achieve the aim, based on the publicly available database we 
found 160 methylated genes from 2000 to 2015 (Table 5.1). We selected five genes 
(GLOXD1, B4GALT1, CHFR, BLMH, miR-129-2) that have been reported to be 
aberrantly methylated by other groups. Using this information, we evaluated individually 
and the combination of the methylation status of these genes in detecting and diagnosing 
HCC. 
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Table 5.1, DNA hypermethylation genes list for HCC from 2000-01-01 to 2015-07-30 
S.NO Genes 
Number of samples 
Reference 
HCC 
Adj 
HCC 
HBV HCV LC NC 
1.  3OST2 33/48 18/48     [26] 
2.  14-3-3Ɛ        
3.  AKAP12 41/48 10/48     [34] 
4.  APC 411/668 20/96 0/19 33/46 76/113 51/99 [36-40,15-18,72,78,21] 
5.  ASS        
6.  B4GALT1 15/27 0/20     [25] 
7.  BASP1        
8.  BCL6B 129/149 20/50    0/8 [40] 
9.  BLMH 28/48 0/48     [29] 
10.  BMP-6 39/60 30/60     [11] 
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11.  BTG3        
12.  CADM1 34/82 9/56    0/8 [12] 
13.  CASP8 
Methylated in both HCC and Adj non-
Cancerous tissue  
 [13] 
14.  CAV1        
15.  CCND2 68/161 10/98    14/25 [14-16] 
16.  CDH1 138/428  0/19 7/38 8/41 32/133 [6, 18-20] 
17.  CD82        
18.  CDO1 52/123  2/29  4/28 0/20 [21] 
19.  CHFR 62/178 1/48    0/60 [1, 27, 28] 
20.  CFTR 73/80 15/55     [16,20, 15] 
21.  CIS 70/80 33/80     [28,76] 
22.  COX-2 33/108 2/48 0/19 0/19 0/30  [26, 6] 
23.  CSRP1 9/16      [22] 
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24.  DACH1 24/57 9/57    0/2 [23] 
25.  DAPK 107/224  0/19 22/51 70/98 13/45 [4,6, 17, 21] 
26.  DENND2D 69/92      [58] 
27.  DKK1 64/216     0/75 [18] 
28.  DKK3        
29.  DLC-1 61/216     0/75 [18] 
30.  DLEC1        
31.  DLGAP5 168/220 22/88     [56] 
32.  DNMT1 24/44    11/35  [31] 
33.  DNMT2 8/44    4/35  [31] 
34.  DNMT3A 30/44    14/35 7/35 [31] 
35.  DNMT3B 17/44    9/35  [31] 
36.  E2F1        
37.  ESR1 40/48      [62] 
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38.  EYA4        
39.  FAM83D 50/72 9/72     [29] 
40.  FAM43B 24/40      [105] 
41.  FBLN1        
42.  FHIT        
43.  GLOXD1 75/160 4/160    2/29 [24] 
44.  GSTP1 322/545 22/97 0/19 0/13 32/93 7/85 [4, 6,16,19,20,72,78,21,121] 
45.  GRASP 17/24      [32] 
46.  GRS17        
47.  GPX3 46/60 0/60     [37] 
48.  HACE1 18/27      [61] 
49.  HAI-2/PB        
50.  HDPR1        
51.  HIC1 32/48 41/48     [26] 
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52.  HINT1 22/40 15/40     [113] 
53.  
HISTIH2A
E 
       
54.  hMLH1 9/110 3/50 0/19 0/13 0/30  [6,121] 
55.  HOXA9 23/30 16/30    1/29 [35] 
56.  IGFBP-7 89/136  8/46   5/35 [59] 
57.  IRAK3 102/160 23/160    1/29 [35] 
58.  JNK1 17/31      [114] 
59.  KL        
60.  KLK10        
61.  KLHL35        
62.  LIFR        
63.  LINE-1 37/75 52/75     [40] 
64.  MAGE-A1        
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65.  MAGE-A3        
66.  MAT1A        
67.  MGMT 81/323 5/50   14/79 17/77 [4, 20,78,21,121] 
68.  MT1G 114/169 8/48 6/37   3/31 [44,45] 
69.  MT1M 59/121  2/37   2/31 [44] 
70.  MTSS1        
71.  MUC2 46/74 14/74     [64] 
72.  NBS1 6/64      [55] 
73.  NORE1B        
74.  NQO1        
75.  NR2E1        
76.  O6MGMT 84/208   20/100 60/108 4/100 [53] 
77.  OPMCL 35/50 32/50     [121] 
78.  OXGR1        
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79.  p14ARF 178/445 23/80 2/24 33/138 61/119 46/158 [19,20,53,57,116,121] 
80.  p151NK4B 196/389 25/50 6/76 20/100 36/108 4/163 [17,34,53,57,77,121] 
81.  P16 510/856 66/344 5/97 23/68 23/121 26/205 
[4,6,14,19,20,34,52,57,72,77,78,109,2
1, 111,121] 
82.  P21 22/50      [34] 
83.  P27 1/50      [34] 
84.  P3000        
85.  P53        
86.  P73 170/289 0/50  28/138 60/108 4/113 [19,53,121] 
87.  PAX        
88.  PCDH10 38/50 20/50     [101] 
89.  PER3        
90.  PENK        
91.  PRDM2        
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92.  PRL-1        
93.  PTEN        
94.  RASSF1A 873/1158 30/144 
16/15
7 
25/53 50/181 8/267 [3,6,8,16,19,34,38,50,68-78] 
95.  RASSF2A 31/45 12/30     [112] 
96.  RASSF10 57/69     0/20 [30] 
97.  RAR-b 15/50 3/50     [121] 
98.  RB 18/64  6/24    [57] 
99.  RECK        
100.  RELN 18/48      [108] 
101.  RIZ1 111/189 3/48    1/17 [4,78,110,115] 
102.  RUNX-3 337/674 32/386    1/100 [4,16,18,39,72] 
103.  SAMSN1 124/144      [36] 
104.  SDPYA        
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105.  SFRP1 215/458 9/47 3/21  9/42 2/115 [4,18,72,102,119, 120] 
106.  SFRP2 54/96  4/21  9/42 2/32 [4, 121] 
107.  SFRP3 36/60  6/37  9/23 0/37 [49] 
108.  SFRP4 3/54  0/21  0/42 0/15 [120] 
109.  SFRP5 33/96  7/42  7/42 2/32 [4, 120] 
110.  SHP1 70/80 73/80     [76] 
111.  SIP1 17/23      [84] 
112.  SKY        
113.  SLIT2 45/48 39/48     [26] 
114.  SOCS1 372/624 56/130    0/17 [4,19,76,99,118,121] 
115.  SOCS2 68/80 20/80     [76] 
116.  SOX1 31/54  3/21  14/42 0/15 [66] 
117.  SOX17        
118.  SPARC 45/60 7/60     [100] 
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119.  SPINT2 64/80   32/50  20/50 [16,33] 
120.  SRD5A2        
121.  SSBP2 14/27 6/18     [8] 
122.  Survivin        
123.  SYK 34/65      [19] 
124.  TFPI2 20/43  4/26   5/26 [98] 
125.  TGR5 77/160  12/88   2/45 [51] 
126.  TIP30        
127.  TIF1Ɣ        
128.  TIG1 48/91 17/91     [60] 
129.  TSPYL5 18/24      [31] 
130.  TUSC1 29/94 2/94     [54] 
131.  UCHL1 12/27      [118] 
132.  UNC5C 11/42      [67] 
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133.  Vimentin 24/43      [105] 
134.  WIF-1 153/321 39/105     [18] 
135.  WT1        
136.  XAF1 43/65      [19] 
137.  XPO4 28/44  9/34  18/38 3/17 [48] 
138.  ZAR1 67/88      [63] 
139.  ZHX2        
140.  ZIC1 72/132 19/132     [46] 
141.  miR-1 18/40      [43] 
142.  miR-9-1 30/80      [57,73] 
143.  MiR-9-2 20/80      [57,73] 
144.  miR-10a        
145.  miR-34a 33/83 22/43     [57, 68] 
146.  miR-34b/c 34/43 23/43     [68] 
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147.  miR-124-1 8/40      [57] 
148.  miR-124-2 5/40      [57] 
149.  miR-124-3 17/40      [57] 
150.  miR-1247 15/40      [57] 
151.  miR-125b        
152.  miR-129-2 127/198 6/75   1/8 0/12 [55-57] 
153.  miR-132        
154.  miR-148a 3/40      [57] 
155.  miR-203 0/40      [37] 
156.  miR-320        
157.  miR-335 18/20 25/32     [86] 
158.  miR-596 11/40      [57] 
159.  miR-663        
160.  miR-9        
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5.1.1. MiR-129-2 as a biomarker 
Micro RNA a group of small noncoding RNA with a length of ~22 nucleotides, 
participates in numerous biological and pathological processes, including development 
regulation, cell proliferation, cardiogenesis, lymphocyte development, adipocyte 
differentiation, and carcinogenesis, through transcriptional or translational repression. 
MiR-129-2 gene is located in a canonical CpG island on chromosome 11, which was 
found to be frequently hypermethylated in endometrial cancer and gastric cancer. Tumor-
specific down-regulation of subsets of miRNAs has been described in the initiation and 
progression of HCC.  
Based on evidence has emerged that epigenetic mechanisms play a crucial role in the 
down-regulation of tumor suppressing miRNAs, and contribute to malignant 
transformation during hepatocarcinogenesis. Based on publicly available data source the 
overall specificity and sensitivity of MiR-129-2 were 92.63% and 64.14%. Based on the 
data we selected MiR-129-2 as a biomarker in our research [55-57]. 
 
5.1.2. CHFR as a biomarker 
 Checkpoint with Forkhead and Ring Finger Domains, E3 Ubiquitin Protein Ligase 
(CHFR) is a protein coding gene. It is located on chromosome 12 from 132, 822, 187 bp 
to 132, 956, 304 bp. primary human tumors and mammalian cell culture models indicate 
that CHFR may function as a potent tumor suppressor. CHFR functions as part of an early 
G2/M checkpoint, more specifically in antiphase. Antiphase refers to late G2 when 
chromosome condensation starts. This early mitotic checkpoint causes a delay in 
chromosome condensation in response to mitotic stresses. The human CHFR gene was 
originally identified during a search for novel cell cycle checkpoint proteins that have 
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fork-head associated domains. Initial analysis indicated that the CHFR-associated G2/M 
checkpoint was inactivated in a subset of cancers as demonstrated by high mitotic indices 
[a high percentage of cells that have condensed chromosomes] in response to exposure 
to the microtubule poison, nocodazole, due to lack of CHFR expression or CHFR 
mutations in various cancers. Many other studies showed promoter hypermethylation 
leading to low/no expression of CHFR.  
Aberrant methylation was detected in 22 of 65 (35%) primary hepatocellular carcinomas 
(HCC), compared to noncancerous liver cells [27]. Also, methylation of CHFR was found 
to be significantly correlated with advanced disease stage (p=0.037) and an infiltrated 
growth pattern (p=0.047). In another study with 70 HCC samples, methylation frequency 
of CHFR was 43% (30 out of 70) [28]. Based on publicly available data source the overall 
specificity and sensitivity of CHFR were 99.19% and 34.83%. based on these values we 
selected CHFR as a biomarker for our research [1,27, 28]. 
 
5.1.3. BLMH as a biomarker 
Bleomycin hydrolase (BLMH) is cytoplasmic cysteine peptidase that is highly conserved 
through evaluation. It is located on chromosome 17 from 30, 248, 195 bp to 30, 292, 166 
bp. However, the only activity of the enzyme is metabolic inactivation of the glycopeptide 
bleomycin (BLM), an essential component of combination chemotherapy regimens for 
cancer. The protein contains the signature active site residues of the cysteine protease 
papain super family.      
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 Based on “Triple-combination array” experiment many genes showed differential 
expression between normal tissue and tumor tissue. Analyzing the data derived from the 
triple-combination array, the bleomycin hydrolase gene was given highest priority of all 
candidate genes because bleomycin is widely used as anti-cancer drugs. Based on 
publicly available data source the specificity and sensitivity of BLMH were 100% and 
58.33%. Based on these results we selected BLMH is a biomarker for our research. 
 
5.1.4. B4GALT1 as a biomarker 
β-1, 4-galactosyltransferase (B4GALT1) is a protein coding gene. It is located on 
chromosome 9p13. This gene is unique among the beta4GalT genes because it encodes 
an enzyme that participates both in glycoconjugate and lactose biosynthesis. It is 
ubiquitously expressed but at very low levels in the fetal and adult brain. This gene 
encodes type II membrane-bound glycoprotein, named β1, 4-Gal-T1, which can transfer 
galactose in a β-1, 4 linkages to acceptor sugars.  B4GALT1 is reported to be involved in 
the synthesis of selectin ligands, the skin wound-healing process, and the inflammation 
reaction.  
The activation of this pathways plays an important role in human hepatocellular 
carcinoma. Based on the previously published papers the sensitivity and specificity of 
B4GALT1 were 55.55% and 100%. We selected as a biomarker for our research [25]. 
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5.1.5. GLOXD1 as a biomarker 
4-Hydroxyphenylpyruvate Dioxygenase Like (GLOXD1) as a protein coding gene. It is 
located on the chromosome 1 from 45, 326, 873 bp to 45, 328, 675 bp. It is an important 
enzyme in the catabolic pathway of tyrosine in the liver.  
Based on the publicly available data the specificity and sensitivity of GLOXD1 were 
96.74% and 46.87% [24]. Based on these results we selected as a biomarker for our 
research.  
 
5.2. Materials and methods  
5.2.1. Collection of clinical tissue specimens 
We analyzed 80 tissue samples, consisting HCC and paired non-HCC liver tissues as 
control (Including 23 patients with HBV, 11 with cirrhosis, 33 with both HBV and 
cirrhosis and 13 without HBV and cirrhosis) in accordance with the institutional ethical 
guidelines. All patients were subjected to pathological diagnosis and classification for the 
different stages. For all patients, liver tissue samples were collected from cancerous and 
the adjacent non-cancerous surgical margin. All of these tissues were stored as formalin-
fixed paraffin-embedded (FFPE) samples. The clinicopathological data of the patients at 
initial diagnosis were listed in Table 5.2. 
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Table 5.2, Clinicopathological parameters of 80 patients used in the independent 
validation study by qMSP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinicopathologic parameters Cases (N = 80), n (%) 
Age (Years) 
Range 
Mean 
 
32-82 
52±9.75 
 Gender 
Male 
   Female 
 
63 (78.75) 
17 (21.25) 
Liver Cirrhosis 
                      Yes 
                      No 
 
42 (52.50) 
38 (47.50) 
HBV 
Yes 
No 
 
54 (67.50) 
26 (32.50) 
TNM stage 
I 
II 
III 
I-II 
II-III 
 
1 (1.25) 
38 (47.50) 
25 (31.25) 
2 (2.70) 
14 (17.50) 
AFP 
≤ 200 
>200 
Unknown 
 
24 (30.00) 
34 (42.50) 
22 (27.50) 
Tumor size 
< 5 cm 
≥ 5 cm 
 
48 (60.00) 
32 (40.00) 
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5.2.2. DNA extraction and purification protocol  
 Cut the tissue with microtome blade 
 Wash the tissue with Xylene [incubate the tissue sample for 15 to 20min]. wash 
the tissue with 100% ethanol, 80% ethanol, two times with PBS 
  Add the 10% SDS kept at 37°c for 1hr than add the Proteinase K and kept for 
overnight at 37 0C 
 Add two volumes of Phenol Chloroform isoamyl alcohol [25:24:1], followed by 
the centrifugation at 10,000 rpm for 5min 
 Collect the supernatant liquid into clean and fresh centrifuge tube 
 Wash the solution with chloroform and collect the aqueous layer 
 Add 1/10 volume of 3M sodium acetate and two volumes of isopropanol  
 Keep the solution at -20 0C for overnight. 
 Centrifuge the solution for 15min at 15,0000 g 
 Discard the liquid and wash the pellet with ice chilled 70% ethanol 
 Air dry the pellet for 10 to 15min 
 Add the 0.1mM of Tris-EDTA 
Once we extract the DNA we calculate the DNA concentration with the help of UV-Vis 
and PCR. By using UV-Vis we measure the absorbance of DNA at A260 nm. DNA 
concentration is estimated by measuring the absorbance at A260 nm, adjusting the A260 
measurement for turbidity (measured by absorbance at 320nm), multiplying by the 
dilution factor, and using the relationship that an A260of 1.0 = 50µg/ml pure dsDNA.  
Concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor × 50µg/ml 
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By using PCR, we plot a standard calibration curve with the help of serial dilution of 
standard genomic DNA along with the samples. With the help of slop, Y-intercept and 
Ct values of the sample we calculate the unknown DNA concentration (Fig: 5.1). As we 
can see the Table 5.3, PCR calculated concentrations are less than the UV-Vis calculated 
concentrations. because in the UV it read all the DNA present in the sample but in PCR 
with the help of β-actin primer amplified DNA only read and gives the Ct value. Based 
on that Ct value we can get the accurate DNA concentration. For our research, we use 
PCR calculated DNA concentration.  
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(A) 
 
 
(B) 
 
Figure 5.1, (A) Standard β-Actin curve. (B) Amplification curve for FFPE 
samples.
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Table 5.3, FFPE tissue DNA samples concentrations 
 
 
 
 
 
 
 
 
 
 
 
S.No 
Normal 
sample 
UV ng/mL PCR concentration 
Cancer 
sample 
UV ng/mL PCR concentration 
1 01-13 695.5 300 01-13C 162.05 80 
2 03-18 302.55 200 03-18C 422.85 280 
3 03-17 343.85 220 03-17C 277.9 180 
4 03-19 436.75 180 03-19C 437.25 90 
5 03-16 533 315.4 03-16C 485.75 201.5 
6 03-18 290.45 90.5 03-18C 529.5 333.9 
7 02-08 597 287.1 02-08C 319.6 115.03 
8 06-15 90.25 11.03 06-15C 0.75 24.5 
9 04-29 111.35 27.36 04-29C 110 25.78 
10 05-10 107.3 27.24 05-10C 63.4 16.74 
11 05-08 132.45 19.15 05-08C 305.3 180.4 
12 04-07 274.75 154.03 04-07C 194.85 32.9 
13 07-23 449.4 265.1 07-23C 224.9 47.29 
14 05-33 254.95 99.9 05-33C 334 29.98 
15 04-08 440 116.74 04-08C 384.3 257.54 
16 02-07 1043.5 334.5 02-07C 476.75 40.78 
17 04-12 490.35 196.04 04-12C 1273 540.79 
18 01-44 551.5 180.5 01-44C 660.5 136.81 
19 03-42 466.4 277.68 03-42C 990 476.81 
20 03-35 472.25 138.46 03-35C 773.5 41.39 
159 
 
5.2.3    Reagent preparation 
5.2.3.1 Preparation of CT-conversion Reagent 
The CT conversion supplied is a solid mixture and 900µL water, 300 µl M-Dilution 
buffer and 50µl M-dissolving buffer to a tube of CT conversion Reagent. It is thoroughly 
mixed with frequent vortexing for 10 minutes. It can be stored at -20 ⁰C. It can also be 
prepared manually, Table 5.4. Light should be avoided a sit is very sensitive and best if 
used immediately after preparation. 
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Table 5.4, CT-conversion reagent 
 
 
Reagent Composition 
Quantity 
96 samples 
Sodium metabisulphite Na2s2O5 5.8g 
M-Dilution buffer 2MNaOH 2880µL 
M-Dissolving buffer 50%dimethyl formamide 480µl 
water H2O 1200µl 
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5.2.3.2 Preparation of M-wash buffer 
24ml of 100% ethanol to the 6ml M-wash buffer or 96ml of 100% ethanol to the 24ml 
M- wash buffer concentrate should be added before use. 
 
5.2.4    Protocol for bisulfite conversion 
prior to sodium bisulfite conversion, DNA concertation was quantified by RT-PCR 
amplification. Standard unmethylated and methylated genomic DNA was purchased with 
CpGenome DNA modification kit (Millipore, Billerica, MA) for establishing a standard 
curve. Different concentration of standard DNA was obtained by serial dilution and then 
amplified with the β-actin (ACTB) primer: 5’ GGCGGCACCACCATGTACCCT 3’ and 
5’ AGGGGCCGGACTCGTCATACT 3’. Sample DNA concentration was calculated 
utilizing the standard calibration curve of cycle numbers and logo concentration. Based 
on these results, the final genomic DNA concentrations of all samples were normalized 
within the same concentration through dilution adjustment. 
1. 130 µl of the CT conversion reagent prepared is added to 20µl of the 
DNA sample ion a PCR Tube. The amount of the input DNA can be from 500pg-
2µg. However, for optimum concentrations, 200-500ng is preferred. 
2. If the DNA sample is less than 20µl, the difference can be made 
up by water. 
3. 2 or 3 µl of Salmon DNA is added to the sample. 
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4. Place the sample tube in the thermo cycler and reaction proceeds in following 
steps 
98 ⁰C for 10min 
64 ⁰C for 150min 
4 ⁰C storage up to 20 hours 
5. The whole process for purification consists of binding of sample, 
desulfonation, binding buffer wash, ethanol wash, and elution. 
6. 600µl of the M-binding buffer is added to the zymo spin IC column and column 
is placed into a collection tube of capacity 800µl. 
7. The sample is added to the column and is inverted several times. It is centrifuged 
at full speed for 30s and flow through is discarded. 
8. 200µl of the M-desulfonation buffer is added to the column and left a room 
temperature for 15-20 min. After the incubation, it is centrifuged for 30s. 
9. 200µL of wash buffer is added twice and centrifuge after each for 
30s. 
10. At the end, the column is placed into a 1.5ml micro centrifuge tube and M-
elution buffer (10Mm of Tris buffer) is added. It is centrifuged for 30s and DNA 
is eluted DNA can be used immediately or stored at -20⁰C for further use. For 
longer time it should be stored below -70 ⁰C 
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5.2.5. Quantitative methylation-specific PCR 
The quantitative methylation analysis was carried out on Bio-Rad CFX96 PCR 
Instrument. The initial concentration of the primer is 100µg. It is available in dry form. 
It is re- suspended by dissolving in the appropriate amount of water. It is then diluted to 
5µmol/L. HRM master mix contains, DNA polymerases, SYBR green dye, optimized 
concentration of Q-solution NTPs and MgCl2. Each 10 μl reactions consisted of 4 μl 
Type-it® HRM master mix, 4 μl of 5 μmol/L of both forward and reverse primers and 
1μl of bisulfite-modified (EZ DNA Methylation-Gold kit) genomic DNA samples. The 
amplification condition was the following: 95 ᵒC denaturing for 10 min, 42 cycles of 95 
◦C for 45 s, gene specific annealing temperature [Table 5.5] for 30 S, and extension at 
72 ᵒC for 45 s. A melting curve was performed to conform the specificity of the PCR 
products. Methylation percentage (MP) was calculated using the following equation:  
MP = (Before qMSP input amount of DNA/after qMSP Calculated amount of DNA) × 
100 
where after qMSP calculated DNA was getting by plotting standard curve by using 
methylated DNA reference. 
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Table 5.5, Primer sequences for quantitative methylation specific polymerase chain reaction 
 
 
 
 
 
 
 
 
Gene Forward Reverse 
Annealing 
Temp [ᵒC] 
B4GALT1 5'- TAGGAAACGGGTTTCGACG -3' 5'- CCGTCCACTTTCTTTACCG -3' 58 
BLMH 5'- AGAAGGCGTCGGCGTCGTTT -3' 5'- TCAACGCCGTCGAAACTAACC -3' 60 
CHFR 5'- TTTCGTGATTCGTAGGCGAC -3' 5'- GCGATTAACTAACGACGACG -3' 58 
GLOXD1 5'- AGGATGTGATTAGGCGTGAGGTTC -3' 5'- AAAAAAACGAAACCCGTAACTCCG-3' 62 
miR-129-2 5'- TTAGTTTGTTCGGTTTTAGGGTTC -3' 5'- CTAAATAACTACCGTCTTCTCGACG -3' 64 
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5.2.6. Specificity and sensitivity of MSP 
The specificity of the MSP assay was evaluated by detecting the bisulfite-modified 
standard unmethylated DNA and Methylated DNA through high-resolution-melting 
(HRM) analysis repeatedly. The melting temperatures for each gene were recorded as 
reference for the patient sample analysis. Sensitivity of MSP was determined by mixing 
bisulfite-modified standard methylated DNA (1%) with standard unmethylated DNA 
(99%) together.  
5.2.7. Statistical analysis 
All statistical analysis was performed with the use of the IBM SPSS 23.0 software for 
windows (studentdiscounts.com). The difference of DNA methylation status between 
different groups was analyzed using the student t-test. Optimum cutoff values for the 
five genes were separately determined by maximizing both specificity and sensitivity 
for the detection of HCC. Receiver-operating characteristics (ROC) curves were 
established to determine a threshold value in distinguishing HCC from adjacent non-
tumor and to determine the area under the curve (AUC). A p value of less than 0.001 
was considered statistically significant. 
 
5.3. Results 
5.3.1. Specificity and sensitivity of MSP method 
The specificity of the MSP method on 5 genes was evaluated using standard 
unmethylated DNA as negative control and methylated DNA as positive control to ensure 
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the completion of bisulfite conversion. In addition, two blank samples, one from the 
blank control added before the bisulfite conversion and the other added before PCR 
reaction, were used to account for false positive. As shown in Fig. 5.2, this highly specific 
test on the MiR-129-2 gene was illustrated in the PCR amplification and the subsequent 
melting curve analysis for standard methylated DNA and unmethylated DNA as well as 
a blank control. The selected primer and optimized PCR conditions ensured that only 
methylated DNA after bisulfite conversion could be amplified for all genes. The 
specificity of these MSP methods is high for all 5 genes. 
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Figure 5.2, The amplification results of standard methylated DNA, 1% 
methylated DNA, standard unmethylated DNA as negative control, and blank 
control are shown in RT-PCR (A) and melting curve analysis (B).
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The sensitivity of the MSP methods was assessed by mixing 1% standard methylated 
DNA and 99% standard unmethylated DNA together. Repeated amplification of the 
mixed sample were performed by RT-PCR. For all 5 genes, the MSP method could 
detect 1% methylation to ensure enough sensitivity of tests (Fig. 5.2). 
During the patient sample MSP analysis, control samples including negative and positive 
control, and two blank sample, as well as 1% standard methylated DNA were amplified 
on the sample plate with patient samples. These controls ensured the completion of 
bisulfite reaction and the reliability of the results. 
 
5.3.2. Quantitative methylation analysis 
Although the promoter methylation on of B4GALT1, BLMH, CHFR, GLOXD1, and 
MiR-129-2, were high in HCC patient samples, the MSP analysis cannot differentiate 
the non-cancerous and cancerous tissue with the assistance of the melting curves. To 
obtain the quantitative information, we further performed RT-PCR methylation analysis 
of these three genes on 80 pairs of matched samples. The quantitative results were 
expressed as methylation percentage, which was determined by the following equation: 
 
 
QM and QTotal were the reference methylated and total DNA quantity, respectively. 
As shown in Figure 5.3, Standard curves were established to determine QM. QTotal means 
total amount of DNA input in RT-PCR.   
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As summarized in Table 5.6, the quantitative results in 80 pairs of matched HCC tissues 
showed higher methylation percentage on genes B4GALT1, BLMH, CHFR, GLOXD1, 
and MiR-129-2 for cancerous samples comparing with the non-cancerous ones. The 
methylation percentage of cancerous tissue was high than in individual tissues.   
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A. 
 
B. 
 
 
Figure 5.3, Standard curve constructed for quantifying methylated DNA for gene 
MiR-129-2 (A) and amplification curve for the MiR-129-2 standards (B) 
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Table 5.6, The methylation percentage of 5 genes and combination of 5 genes on 80 pair 
of HCC cancerous/non-cancerous samples 
 
 
 
 
 
 
Gene 
HCC Cancerous 
Samples 
(Average) 
Non-Cancerous 
Samples 
(Average) 
N 
B4GALT1 41.26 4.16 58 
BLMH 59.78  2.71 43 
CHFR 45.83 3.47 45 
GLOXD1 59.72 7.26 50 
MiR-129-2 54.41 3.48 60 
Combination of 5 Genes 70.88 3.29 79 
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5.3.3. Gene-specific promoter methylation analysis 
In epigenetic studies of HCC, the aberrant promoter methylation of B4GALT1, BLMH, 
CHFR, GLOXD1, and MiR-129-2 was frequently reported in previous studies [1, 24-
30]. We checked the status of promoter hypermethylation for five genes in 80 liver tissue 
samples including 23 with HBV, 11 with cirrhosis and 13 without HBV and cirrhosis and 
for further validation using MSP. The AUC for the individual gene in discriminating 
HCC from adjacent non-HCC was moderate (GLOXD1: 0.695, B4GALT1: 0.721, 
CHFR: 0.672, BLMH: 0.649 and miR-129-2: 0.773). The methylation status was 
considered to be positive. All five genes exhibited higher methylation frequencies in 
HCC than adjacent non-HCC (p<0.001), and the combination analysis resulted in an 
increased AUC of 0.975 with 93.7% of sensitivity and 100% of specificity, 100% PPV, 
and 94.1% NPV, respectively (Table 5.7 and Fig. 5.5). By adjusting the individual cut-
off value of all genes (37.05% of GLOXD1, 31.05% of B4GALT1, 20.17% of CHFR, 
30.85% of BLMH and 31.39% of miR-129-2). All samples were examined in this study 
had methylation in at least one gene. 
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(A) 
 
 
 
 
 
 
 
(B) 
 
 
Figure 5.4, Standard curve constructed for quantifying methylated DNA for 
combination of 5 genes (A) and amplification curve for the combination of 5 genes (B) 
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Table 5.7, Diagnostic ability of five methylated genes based on qMSP analysis 
 
 
 
 
 
 
  
  
Genes 
AUC 
[95%CI] 
Cut-off 
value 
[%] 
Sensitivity 
[%] 
Specificity 
[%] 
PPV 
[%] 
NPV 
[%] 
GLOXD1 0.695 37.1 51.2 98.7 98.8 67.2 
B4GALT1 0.721 31.1 47.5 100 100 65.6 
CHFR 0.672 20.2 50 100 100 66.7 
BLHM 0.648 30.8 48.7 100 100 66.1 
miR-129-2 0.772 31.4 62.5 100 100 72.7 
GLOXD1, B4GALT1, CHFR, BLHM and miR-129-2 0.975  93.7 100 100 94.1 
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Figure. 5.5, Receiver-operating characteristics (ROC) curve for the combined 
analysis of DNA methylation levels (GLOXD1, B4GALT1, CHFR, BLMH, and miR-
129-2) in 80 paired HCC and adjacent non-tumorous tissues. AUC: area under the 
curve. 
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5.3.4. Methylation levels of multigene in HCC 
At first, the methylation status of these five genes were evaluated using MSP in 80 paired 
HCC and adjacent NT tissues and revealed that the MPs of all genes were higher in tumor 
tissues compared with adjacent NT samples (student t-test, p< 0.0011). The MPs of these 
five genes for all 80 samples are shown in Fig. 5.5. We found the clear differentiation 
between HCC and NT (Fig. 5.7. P<0.0001). The diagnostic ability of these five methylated 
genes and combination was evaluated using ROC curve analysis. The AUC for each 
individual gene was low to moderate (range: 0.649 to 0.773, Fig. 5.8). However, the 
combination analysis of these five genes resulted in an increased AUC of 0.975 with 93.7% 
sensitivity, 100% specificity, 100% positive predictive value (PPV), and 94.1% negative 
predicative value (NVP) in discriminating HCC from adjacent NT tissues.  
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Figure. 5.6, Quantitative methylation results of qMSP on hepatocellular carcinoma and adjacent non-tumorous 
tissues The line represents the cut-off value. Mann-Whitney U test was used to determine statistical significance. 
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Figure. 5.7, Quantitative methylation results of qMSP for combined genes on 
hepatocellular carcinoma and adjacent non-tumorous tissues. 
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Figure. 5.8, Receiver-operating characteristics curves for individual gene analysis of 
DNA methylation levels in discriminating HCC from adjacent non-cancerous 
tissues. 
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5.3.5. Correlation with clinicopathologic parameters 
For the evaluation of the biological significance of hypermethylation of these five genes in 
the HCC, we assessed the associations between the hyper-methylation status of these five 
genes and clinic-pathological parameters. In tumor samples, no correlation was found 
between the MPs of any genes and the clinicopathological parameters, such as patient age 
or gender, tumor differentiation and size, HBV and liver cirrhosis infection, tumor size and 
serum AFP levels of any five target genes.  
 
5.4. Discussion 
Hepatocellular Carcinoma is the most aggressive malignant tumor worldwide with a 
minimal outcome. Early detection and accurate discrimination between HCC and adjacent 
NTs may offer an opportunity to improve the long-term survival for HCC patients. 
Aberrant promoter methylation plays an important role in the process of tumorigenesis and 
biomarker discovery for disease diagnosis. To identify and characterize emerging markers 
in hepatocellular carcinoma, we used qMSP to evaluate a panel of genes among HCC and 
adjacent NTs. In this study, we decided to investigate the promoter methylation status of 
five genes (GLOXD1, B4GALT1, CHFR, BLMH, miR-129-2). These genes are involved 
in different molecular pathways of carcinogenesis such as cell proliferation (miR-129-2), 
apoptosis (B4GALT1 and CHFR). Understanding their functions in the advance tumor 
stages of HCC provides the ability to predict the premalignant conditions for early 
diagnosis. 
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The aberrant promoter methylation of numerous genes (GLOXD1, B4GALT1, CHFR, 
BLMH and miR-129-2) has been reported to be associated with liver carcinogenesis [24-
32]. However, most of these studies evaluated the methylation status using non-quantitative 
methods. In this study, we performed quantitative methylation analysis for five selected 
TSGs. The qMSP method that we developed reveled that quantitative methylation analysis 
could provide more accurate and flexible information than non-quantitative analysis. For 
example, we could filter out low level background methylation by setting a proper cutoff 
value, and thus, improving clear discriminating between HCC and non-cancerous adjacent 
tissues. When compared sodium bisulfite based assays, qMSP is a rapid, easy-handling and 
cost-effective quantitative method that is particularly suitable for quantitative analysis of 
DNA methylation in clinical samples with a small amount of DAN. Several similar studies 
on qMSP, MSRE-based methods have also been reported. In a recent study, Moribe er al, 
D. Hua et al, Z-H. Huang et al [20, 23, and 33] reported that a qMSP, MSRE-based qPCR 
procedures were suitable in quantifying methylation levels on small amount of DNA (e.g., 
formalin-fixed and paraffin-embedded tissues).  The major difference between our assay 
and the assays used by others are sodium bisulfite reaction by using the EZ DNA 
Methylation-Gold Kit (Zymo Research, Irvine, CA), cheaper qPCR fluorescent dye (Eva 
green) and a simpler calculation formula for MP in our method.  
The five genes (GLOXD1, B4GALT1, CHFR, BLMH and miR-129-2) identified by qMSP 
as having the discriminatory power to identify HCC samples in this study affect different 
cellular signaling pathways. Among all five TSGs, the most frequently methylated genes 
were miR-129-2, GLOXD1 and CHFR, which are hypermethylated in more than 50% of 
HCCs. In addition, we found that 100% of the cases of HCC had at least one promoter 
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methylated in a panel of five targets (MiR-129-2, GLOXD1, CHFR, BLMH, and 
B4GALT1), suggesting that these genes may be potential biomarkers for HCC in the world 
populations. In Chinese populations, different combinations of methylation markers have 
been proposed for the diagnosis of HCC. APC, GSTP1, RASSF1A or SFRP1 showed 
84.7% sensitivity and 87.8% specificity in discriminating between HCC and normal plasma 
samples and APC, GSTP1, RASSF1A, CDKN2A or RUNX3 showed 85.1% sensitivity 
and 89.4 specificity in discriminating between HCC and non-HCC tissues [23, 33]. The 
reasons for the discrepancies among studies may include different methodologies, samples 
types and patient populations.    
Most HCCs are initiated as minute nodules. Dysplastic changes, which mark the transition 
to small, well differentiated HCCs, usually the nodules measure between 1 and 2 cm in 
maximum diameter. At this stage, tumors are easily detected by using various imaging 
techniques including CT-scan, MRI, and ultrasonography; however, it is not easy to 
discriminate pathologically between small size HCC and benign tumors such as dysplasia.  
The best way for an accurate diagnosis of this particular cancer may be to identify 
molecular changes that govern the transition to cancer. In this study, we found that the 
background liver tissues in HCC patients, where cirrhosis and chronic viral infection, also 
carried clear methylation of multiple genes when compared to adjacent non-tumor tissues, 
we also clearly detect tumor size I and II and discriminate with adjacent NT's tissues. The 
methylation analysis of these targets may not only be clinically useful in distinguishing 
HCC form adjacent NT's tissues but may also provide important information on the risk 
evaluation of HCC. 
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5.5. Conclusion 
In conclusion, we examined the methylation levels of five genes in HCC and corresponding 
NT samples using modified qMSP method, and found that hypermethylation of a panel of 
three genes could efficiently distinguish HCC from adjacent NT samples. However, the 
value of these five genes or their combination for the diagnosis or risk evaluation of HCC 
needs to be further validated. In future, the quantitative methylation assays with an early 
stage of HCC samples will be required to gain new insights into our current findings and 
to identify an optimal combination of methylation markers with higher sensitivity and 
specificity for the diagnosis of HCC. The data from the present study showed that 
quantitative analysis of multiple methylated genes in tissue may be a promising tool for 
prognostic markers of HCC. 
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CHAPTER VI 
 
FUTURE RECOMMENDATIONS 
 
6.1. Pharmacokinetic studies of anti-parasitic drug (BMCL26) in rat models  
In this work, an LC-MS/MS method was developed for the determination of BMCL26 in 
rat plasma. The current work mainly focuses on the pharmacokinetic studies of BMCL26 
in rat models. The pharmacological analysis of the drugs consists of two major 
components, pharmacokinetic studies and pharmacodynamic studies, which help to 
describe what the body does to a drug (PK), and what a drug does to/for the body (PD).  
Today, the pharmaceutical analysis is employed throughout the whole drug discovery and 
development process. It is used to provide accurate and precise data, not only supporting 
drug discovery and development but also post-market surveillance [1-4]. Pharmacokinetic-
pharmacodynamic relationships are playing an increasingly important role in decisions on 
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the rational development and use of new drugs, and they can provide a detailed knowledge 
of the mechanism of the drug and a better understanding of the molecular targets on which 
they act. Due to the significance of pharmacological analysis, sensitive analytical methods 
are critically needed for pharmacological studies. Therefore, our long term goal is to 
provide guidelines in pharmacological studies of the anticancer drugs by quantitatively 
evaluating the molecular mechanisms of the drugs.  
 
6.1.1. Experimental methods and design 
The experimental protocol was approved by the ethical committee.  
 
6.1.1.1. Animals 
Male SPF Sprague-Dawley rats (240-280g, Charles River, Wilmington, MA) are used 
throughout the study. In addition, the pharmacokinetics profile varies between different 
animal species. Rats have been broadly used for safety and efficacy testing. 
 
6.1.1.2. Number of rats: 
A sample size of ten rats will be required in this research. In those ten rats four rats for 
training in anesthesia, drug administration, and blood sampling. One rat for testifies the 
dose of the drug. Then the optimized procedure will be used for a pharmacokinetic study 
on other five rats. 
203 
 
6.1.1.3. Drug administration 
The compound is dosed via 
1) Intravenous administration (IV) 
2) Oral administration 
The drug administration will be given by propylene glycol and saline (v/v 1:1). Depending 
on IC50 of the test compound, the compound dose will be calculated according to the 
following formula: {(IC50 /L*10
-3* molecular weight of compound/mole)/(1kg/L) when 
considering the body density of the Rat is roughly 1kg/L} multiple Blood samples 
(approximately 0.15ml) will be collected into heparinized-tubes before the dose and at 11 
time points (at 0, 5, 15, 30 min, 1, 2, 4, 6, 8, 12, and 24 hr) after dose. 
 
6.1.1.4. Multiple blood sampling 
Blood samples (~ 0.2ml) are collected from tail vein cannula (if the cannulation failed, 
blood will be withdrawn from a lateral saphenous vein). Temporary cannulation of the 
lateral tail vein should be considered because multiple blood samplings are required over 
a short period of time as it avoids multiple needle entries without repeat damage to the tail 
vein. By using this temporary cannula, we reduce the number of needle entries and reduce 
the time the rat spends in a warming cabinet (since warming may not be necessary for 
taking blood via the temporary cannula). Tail bleeding normally requires the rats to be 
warmed in order to dilate the blood vessel prior to taking the sample. 
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No surgery is required. An intravenous catheter is inserted into the vein by puncturing the 
skin and taped in situ. A heparin flush is used (0.1 ml) after placement and between samples 
to prevent clotting. An access port is inserted into the exteriorized end of the cannula, which 
stops the blood from flowing, and the catheter is taped into place. Aseptic technique should 
be used. A local anesthetic cream (e.g. EMLA cream) can be applied to the site 30 minutes 
prior to insertion of the catheter. The tail may need to be washed with diluted Hibiscrub 
(1%) in order to see the blood vessel. The plasma samples will be obtained by 
centrifugation at 15000 rpm for 1 min and stored at -200C until analysis. 
 
6.1.2. Analysis: 
6.1.2.1. Sample extraction 
Protein precipitation (PPT) method will be used for the preparation of plasma samples 
because it is simple and fast. Plasma samples are removed from -20 0C freezer and thawed 
to room temperature; the samples are deproteinized with 800 µl of HPLC grade 
Acetonitrile by vortex-mixing for 30 secs, and were ultra-sonicated for 15mins followed 
by centrifugation at 24,000 × g for 15 min. The supernatant was transferred into auto 
sampler vials and the samples were analyzed using LC-MS/MS. 
The PK analysis will be performed using Winnonlin program. For the multiple sampling 
methods, the analysis will be carried out on the plasma concentration time profiles obtained 
from each animal (n=3) (the concentration of CSUOHO901 in rat plasma on Y-axis and 
time on X-axis plot a graph for both routes of administrations). The PK parameter 
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calculations will be observed for maximum plasma concentration (C max), the time to reach 
maximum plasma concentration (T max), plasma half-life (t1/2) and exposure of the 
compound calculated by the area under the curve (AUC last and AUC inf). For the 
comparison of the injection routes the major parameters of half-life [t1/2], the volume of 
distribution (Vd), total plasma clearance (Cl) and area under the curve (AUC last and AUC 
inf) will be determined for each individual animal after multiple sampling to allow inter-
animal comparisons. 
 
6.1.2.2. Area under curve 
AUC is an important parameter in pharmacokinetic studies; it can be presented graphically 
as the area under the plasma concentration (Y-axis) versus time curve (X-axis). AUC 
provides a measure how much and how long a drug stays in a body. 
The Area under the Curve (AUC) is the area under the concentration/time curve calculated 
using the linear trapezoidal rule. In a single-dose study, the AUC (0-¥) is usually calculated 
in two steps – the linear trapezoidal rule up to the last sampling point above the limit of 
quantitation, plus extrapolation to infinity. 
 
6.1.2.3. T max 
The time after administration of a drug when the maximum plasma concentration is 
reached. 
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6.1.2.4. C max 
C max is the maximum observed concentration from time 0 to the last observed 
concentration for each subject. 
 
6.1.2.5. T half-life 
The half-life is the time taken for the plasma concentration to fall to half its original value. 
Units for this parameter are units of time such as hour, minute, or day. 
T1/2 = 0.693 / Ke 
 
 
 6.1.2.6. Volume of distribution [Vd] 
The volume of distribution relates a concentration of drug measured in the blood to the 
total amount of the drug in the body. This mathematically determined value gives a rough 
indication of the overall distribution of the drug in the body. 
Vd = Amount of drug in the body at time t (At) / C plasma at time t 
 
6.1.2.7. Clearance 
Clearance can involve both metabolisms of the drug to a metabolite and excretion of the 
drug from the body. 
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In the broadest sense total (systemic) clearance is the clearance of the drug by all routes 
total (systemic) clearance (Cl) can be calculated by either of the equations given below. 
Cl = Vd x Ke 
Or 
Cl = Dose / AUC 
 
6.1.2.8. Bioavailability (F) 
Bioavailability is defined as the fraction of the administered drug reaching the systemic 
circulation as intact drug. Bioavailability is highly dependent on both the route of 
administration and the drug formulation. 
Subcutaneous, intramuscular, oral, rectal and other extravascular routs of administration 
require that the drug is absorbed first which can reduce bioavailability. The drug also may 
be subject to metabolism prior to reaching the systemic circulation, again potentially 
reducing bioavailability. 
F = Dose iV./ Dose other x (AUC0- ∞) other / (AUC0-∞) i.V. 
 
 
6.2.  Development of novel blood DNA test for early detection of hepatocellular 
carcinoma  
Blood DNA test based on detecting tumor-associated DNA markers in blood is a highly 
promising method for HCC screening. Circulating tumor cells are detected in the blood 
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stream or lymphatic. Because blood circulates throughout the body and transports various 
cells, we have lesser biomarkers that are available for detection of HCC by using blood 
samples. The specificity and sensitivity of particular biomarkers are less, therefore by using 
blood samples we can identify the HCC in early stages (the tumor size is < 3mm) and 
investigate the methylation levels of multiple genes in hepatocellular carcinoma and to 
identify the best biomarkers combination from various biomarkers by sensitivity and 
specificity of genes. Recently biomarkers targeting tumor DNA in blood samples have 
shown clinical utility as a non-invasive “liquid biopsy” for solid tumors. For example, the 
plasma-based septin 9 (SEPT9) hypermethylation assay has been used clinically in 
colorectal cancer [11, 12]. Studies have also supported the use of a blood-based INK4A, 
h19, IGF2, APC, P16, and PADI4 methylation assay as a biomarker for HCC [5-10]. The 
sensitivities and specificities are from 39.5 – 65.3 % and 65.3 – 87.2 %. In order to achieve 
the better sensitivity and specificity for circulating free DNA methylation analysis, we plan 
to combine the best single biomarkers and run as a single marker. For this work, we already 
detected better sensitivity and specificity panel of biomarkers on both HCC and normal 
tissue samples that can be used in future blood DNA test. 
 
6.2.1. Experimental methods and design 
6.2.1.1. Extraction of DNA from blood/plasma sample 
Collect the blood/plasma samples form GLC biotechnologies laboratory. DNA is isolate 
from 600 µl plasma using TIA Namp Micro DNA kit following the manufactures protocol. 
To improve the extraction efficiency, carrier RNA will be added after the proteinase K 
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digestion. Plasma DNA is eluted in the final volume of 30 µl sterile water and stored at -
20 0C until use. 
 
6.2.1.2. Sodium bisulfite conversion 
Extracted DNA (200 ng to 1µg) has to be used for sodium-bisulfite treatment. Chemical 
modification of unmethylated cytosine to uracil within CpG Island will be performed using 
sodium-meta bisulfite treatment and its purification can be achieved by using EZ DNA 
Methylation-Gold kit. Then the bisulfite treated DNA will be collected by using M-Elution 
buffer (10mm of tris buffer) and stored in -20 0C. The modified DNA is used as a template 
for RT-PCR analysis. 
 
6.2.1.3. Methylation analysis 
Quantitative real-time PCR will be performed on Bio red CFX instrument. Bisulfite-
converted standard DNA samples of know concentration is serial dilute and amplified 
using bisulfite converted ACTB primer. The standard curve prepared from this step is used 
for determining reference quantity of total DNA (Q total) amount for each patient sample.  
Amplification will be performed in a 10 µl reaction volume containing 4 µl of modified 
DNA, 1 µl of primer (biomarker), and 5 µl of master mix (MgCl2 solution, 10X PCR buffer, 
dNTPs and Taq polymerase). RT-PCR is conducting by using CFX96 Real-Time PCR 
detection system for 42 cycles, each of which consists of incubation at 95oC for 10 min, 
denaturation at 95oc for 20 secs, annealing at 66oc for 30 sec, and extension at 72 0C for 45 
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sec. these three steps run 41 cycles than extension at 72 0C for 3 min, annealing at 95 0C 
for 1 min, extension at 60 0C for 1 min, followed by melting curve from 60 0C to 95oC read 
every 0.1 C hold. A positive control and a negative control (distilled water without DNA) 
are included for each of amplification. The specificity and sensitivity of each biomarker 
are analyzed by using Bio Red CFX manager software. Methylated percentage (MP) will 
be used to indicate the methylation level of target CpG sites at a specific location in the 
promoter. MP is calculating using the following equation: 
MP = (QM /Qtotal) x 100% 
 
 
6.2.1.4. Statistical analysis 
The difference between HCC and non-HCC patients will be analyzed using the Mann-
Whitney U test or chi-square test where appropriate. Receiver-operating characteristic 
(ROC) curves will establish to determine a threshold value in distinguishing HCC and non-
HCC and to determine the area under the curve (AUC). 
 
6.2.1.4.1. Specificity and sensitivity of biomarkers 
The specificity (likelihood of obtaining a negative result when the target is not present. or 
probability that a test result will be negative when the disease is not present) of the 
biomarkers assay by detecting the bisulfite-modified cancerous and noncancerous DNA 
through high-resolution-melting (HRM) analysis repeatedly; The melting temperature for 
each gene will be recorded as reference for the patient sample analysis. Sensitivity 
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(likelihood of obtaining a positive result when the target is actually present. or probability 
that a test result will be positive when the disease is present) of biomarkers will be 
determined by using the cancerous DNA 
Specificity = (True negative/ Total number of samples without Cancer) x 100 
Sensitivity = (True positive / Total number of cancer with Cancer) x 100 
 
6.2.1.4.2. Likelihood ratio 
A final term sometimes used with reference to the utility of tests is the likelihood ratio. 
This is defined as how much more likely is it that a patient who tests positive has the disease 
compared with one who tests negative.  
Likelihood ratio = Sensitivity / 1- Specificity 
 
6.2.1.4.3. Positive predictive value: 
Positive predictive value of a test is a proportion that how likely it is that this patient does 
not have the disease given that the test result is positive.  
Positive predictive value = (True positive / true positive + false positive) 
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6.2.1.4.4. Negative predictive value: 
Negative predictive value of a test is a proportion that how likely it is that this patient has 
patient has the disease given that the test result is positive.  
Negative predictive value = (True negative / True negative + false negative) 
 
6.2.1.4.5. Receiver operator characteristic curves 
 Receiver operator characteristic curves (so called because they were originally devised by 
radio receiver operators after the attack on Pearl Harbor to determine how the US radar had 
failed to detect the Japanese aircraft) are a plot of (1-sppecificity) of attesting on the X-axis 
against its sensitivity on the Y-axis for all possible cut-off points. The area under the curve 
(AUC) represents the overall accuracy of the test with a value approaching 1.0 indicating 
a high sensitive and specificity. If an AUC value approaching 0.5 indicating that sensitivity 
and specificity is not better than tossing a coin.  
 
6.2.1.5. Combination of biomarkers 
In this specific aim, we follow a similar method as the previous one which was used for 
the identification of better biomarkers combination in tissue samples. Using the above 
method, we identify the better biomarker combination for the early detection of the HCC 
in both cancerous and non-cancerous patients in serum samples. 
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